Interim / Quarterly Report • Sep 23, 2015
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
Interim condensed financial statements for the period from 1 January 2009 to 30th September 2009 in accordance with International Financial Reporting Standards
| Page | |
|---|---|
| Interim Condensed Financial Statements | |
| Consolidated Statement of Total Comprehensive Income for the nine month period ended 30th September 2009 |
4 |
| Company Statement of Total Comprehensive Income for the nine month period ended 30th September 2009 |
5 |
| Consolidated and Company Statement of Financial Position | 6 |
| Consolidated Statement of Changes in Equity for the nine month period ended 30th September 2009 |
7 |
| Company Statement of Changes in Equity for the nine month period ended 30th September 2009 |
8 |
| Consolidated and Company Cash Flow Statement for the nine month period ended 30th September 2009 |
9 |
| Notes to the Interim Condensed Consolidated and Company Financial Statement | 10-68 |
| Data and information for the nine month period ended on 30th September 2009 | 69-70 |
| GROUP | |||||
|---|---|---|---|---|---|
| Note | 1/1-30/9/2009 | 1/1-30/9/2008 | 1/7-30/9/2009 | 1/7-30/9/2008 | |
| STATEMENT OF COMPREHENSIVE INCOME | |||||
| Sales revenue | 6 | 195.404 | 187.000 | 60.634 | 57.620 |
| Less: Cost of goods sold | (153.143) | (150.474) | (48.051) | (46.408) | |
| Gross profit | 42.261 | 36.526 | 12.584 | 11.212 | |
| Other operating income | 3.809 | 3.436 | 1.088 | 2.181 | |
| 46.071 | 39.961 | 13.671 | 13.393 | ||
| Administrative expenses | (20.887) | (19.468) | (7.673) | (6.296) | |
| Research and development expenses | (179) | (111) | (63) | (58) | |
| Selling expenses | (1.913) | (1.403) | (511) | (520) | |
| Other operating expenses | (1.043) | (2.332) | (285) | (751) | |
| Operating results | 22.049 | 16.647 | 5.139 | 5.767 | |
| Finance cost | 7 | (14.135) | (15.949) | (5.994) | (5.816) |
| Result of ordinary activities | 7.914 | 698 | (855) | (49) | |
| Income (Losses) from investments | 8 | (1.570) | (14.363) | (764) | 1.397 |
| Comprehensive income before tax | 6.344 | (13.665) | (1.619) | 1.348 | |
| Income tax | 9 | (2.467) | 1.864 | (333) | 2.293 |
| Comprehensive income after income tax | 3.877 | (11.801) | (1.952) | 3.641 | |
| Attributable to: | 0 | 0 | 0 | 0 | |
| - Owners of the parent | 412 | (8.188) | (1.920) | 1.846 | |
| - Minority interests | 3.465 | (3.613) | (31) | 1.795 | |
| Other total comprehensive income after taxes: |
|||||
| Valuation of available for sale financial assets at fair value |
778 | (4.232) | (1.271) | (4.232) | |
| Income tax on other total income | (156) | 3.220 | 257 | 3.220 | |
| Total comprehensive income after tax | 622 | (1.012) | (1.013) | (1.012) | |
| Aggregated total comprehensive income after tax | 4.499 | (12.813) | (2.965) | 2.629 | |
| Attributable to: | |||||
| - Owners of the parent | 799 | (9.026) | (2.573) | 1.009 | |
| - Minority interests | 3.700 | (3.788) | (392) | 1.620 | |
| Earnings per share (€ per share) | |||||
| Basic | 10 | 0,0116 | (0,2140) | (0,0505) | 0,0481 |
| COMPANY | ||||||
|---|---|---|---|---|---|---|
| Note | 1/1-30/9/2009 | 1/1-30/9/2008 | 1/4-30/9/2009 | 1/4-30/9/2008 | ||
| STATEMENT OF COMPREHENSIVE INCOME | ||||||
| Sales revenue | 2.561 | 5.417 | 641 | 2.432 | ||
| Less: Cost of goods sold | (2.315) | (4.545) | (657) | (1.511) | ||
| Gross profit | 246 | 872 | (15) | 921 | ||
| Other operating income | 298 | 555 | 97 | (187) | ||
| 544 | 1.427 | 82 | 734 | |||
| Administrative expenses | (494) | (692) | (119) | (72) | ||
| Selling expenses | 0 | (0) | 0 | 7 | ||
| Other operating expenses | (14) | (27) | (4) | (14) | ||
| Operating results | 36 | 707 | (41) | 654 | ||
| Finance cost | 7 | (1.446) | (2.080) | (425) | (457) | |
| Result of ordinary activities | (1.410) | (1.373) | (466) | 197 | ||
| Income (Losses) from investments | 8 | 0 | 1.560 | 0 | 259 | |
| Comprehensive income before income tax | (1.410) | 187 | (466) | 456 | ||
| Income tax | 9 | 95 | 764 | 55 | 493 | |
| Comprehensive income after income tax | (1.315) | 951 | (410) | 949 | ||
| Attributable to: | ||||||
| - Owners of the parent | (1.315) | 951 | (410) | 949 | ||
| - Minority interests | 0 | 0 | 0 | 0 | ||
| Other total comprehensive income after taxes: | ||||||
| Valuation of available for sale financial assets in fair value |
59 | 0 | 0 | 0 | ||
| Revaluation of fixed assets at fair value | 0 | 0 | 0 | 0 | ||
| Tax income on other total income | (15) | 0 | 0 | 0 | ||
| Total comprehensive income after tax | 44 | 0 | 0 | 0 | ||
| Aggregated total comprehensive income after tax | (1.271) | 951 | (410) | 949 | ||
| Attributable to: | ||||||
| - Owners of the parent | (1.271) | 951 | (410) | 949 | ||
| - Minority interests | 0 | 0 | 0 | 0 | ||
| Earnings per share (€ per share) | ||||||
| Basic | 10 | (0,0326) | 0,0236 | (0,0101) | 0,0235 |
| STATEMENT OF FINANCIAL POSITION | GROUP | COMPANY | |||
|---|---|---|---|---|---|
| ASSETS | Note | 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 |
| Non current assets | |||||
| Tangible assets | 11 | 397.270 | 370.186 | 4.267 | 4.588 |
| Intangible assets | 12 | 4.693 | 5.577 | 253 | 900 |
| Goodwill | 13 | 132.884 | 130.463 | 521 | 521 |
| Participations in subsidiaries | 14 | 0 | 0 | 106.466 | 106.405 |
| Participations in associates | 7.083 | 6.423 | 0 | 0 | |
| Available for sales financial assets | 15 | 38.584 | 47.747 | 6.855 | 8.516 |
| Investment property | 30.638 | 30.628 | 34.881 | 34.871 | |
| Long term assets | 16.830 | 16.614 | 6 | 6 | |
| Deferred income tax assets | 2.185 | 1.925 | 0 | 0 | |
| Total non current assets | 630.169 | 609.563 | 153.249 | 155.807 | |
| Current assets | |||||
| Inventories | 26.074 | 27.064 | 62 | 1.162 | |
| Trade and other receivables | 16 | 224.635 | 194.168 | 1.393 | 1.885 |
| Financial assets at fair value through income statement | 9 | 9 | 0 | 0 | |
| Cash and cash equivalents | 33.538 | 38.386 | 232 | 152 | |
| Total currents assets | 284.255 | 259.627 | 1.686 | 3.198 | |
| TOTAL ASSETS | 914.424 | 869.189 | 154.936 | 159.005 | |
| EQUITY AND LIABILITIES EQUITY |
|||||
| Share capital | 24.712 | 24.712 | 24.712 | 24.712 | |
| Share premium | 33.373 | 33.373 | 33.373 | 33.373 | |
| Reserves | 4.903 | 4.047 | 4.993 | 4.690 | |
| Retained earnings / (losses) | 58.729 | 59.356 | 35.752 | 37.326 | |
| Treasury shares | 17 | (12.866) | (12.866) | (917) | (917) |
| Total equity attributable to Group shareholders | 108.851 | 108.622 | 97.913 | 99.184 | |
| Minority interests | 116.389 | 116.714 | 0 | 0 | |
| Total equity | 225.240 | 225.336 | 97.913 | 99.184 | |
| LIABILITIES | |||||
| Long-term liabilities | |||||
| Borrowings | 18 | 313.761 | 301.497 | 35.489 | 35.969 |
| Provision for staff retirement indemnities | 19 | 6.985 | 6.468 | 166 | 125 |
| Deferred income tax liabilities | 20 | 3.273 | 4.247 | 393 | 860 |
| Grants receivable for investments in fixed assets | 26.127 | 27.839 | 6.801 | 6.972 | |
| Other long-term liabilities | 1.158 | 1.163 | 0 | 0 | |
| Total long-term liabilities | 353.998 | 344.008 | 42.850 | 43.926 | |
| Short-term liabilities | |||||
| Trade payables & other liabilities | 21 | 204.545 | 176.779 | 2.798 | 4.826 |
| Borrowings | 18 | 118.725 | 108.700 | 10.777 | 10.595 |
| Short term Income tax payable | 11.917 | 14.366 | 597 | 474 | |
| Total short-term liabilities | 335.186 | 299.845 | 14.172 | 15.895 | |
| Total liabilities | 689.184 | 643.853 | 57.022 | 59.821 | |
| TOTAL EQUITY AND LIABILITIES | 914.424 | 869.189 | 154.936 | 159.005 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Sh are Ca ital p |
Sh are miu pre m |
Diff ere nce s fro m alu atio rev n of t/tio & par ns urit ies sec |
Sta tuto ry Re ser ve |
Me rge r res erv e |
Tax res erv es |
Co rtib le nve bon d lo an res erv e |
Re val uat ion of inv est nts me at f air val ue res erv e |
Re val uat ion of r eal est ate ty a t pro per fair lue va res erv e |
Re tain ed nin ear gs / ( los ) ses |
Tre asu ry Sh are s |
Min orit y inte ts res |
To tal |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ad jus ted ba lan at 1st Ja 200 8 in dan wit h ce as nua ry ac cor ce IFR S |
24 .71 2 |
11 7.2 03 |
14 6 |
1.8 33 |
( 56 .37 8) |
7.2 53 |
2.2 75 |
0 | 19 .30 0 |
20 .73 2 |
( 12 .72 3) |
134 .23 4 |
25 8.5 88 |
| Aju ste d to tal hen siv e in e fo r th erio d 1 /1- 30/ 9/2 008 com pre com e p afte r ta x (s not e 5 ) ee |
0 | 0 | 0 | 0 | 0 | 0 | 0 | ( 1.9 24 ) |
1.0 86 |
( 8.1 88 ) |
0 | ( 3.7 88 ) |
( 12 .81 3) |
| Div ide nds id pa |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ( ) 1.4 02 |
( ) 1.4 02 |
| Ch e in due dis trib utio to ang res erv es n |
0 | 0 | 0 | 10 1 |
0 | 0 | 0 | 0 | 0 | ( 1) 10 |
0 | 0 | 0 |
| Inc in s har ital thr h c ital iza tion of sha ium rea se e c ap oug ap re p rem |
51 .89 1 |
( 51 .89 1) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| of offs Re duc tion sha ital to et p iou s' lo re c ap rev s y ear sse s |
( 47 .83 9) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47 .83 9 |
0 | 0 | 0 |
| Re duc tion of sha ital by ing sh har eho lde ret to s re c ap urn ca rs |
( ) 4.0 51 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ( ) 4.0 51 |
| Sh ital inc are ca p rea se exp ens es |
0 | ( 58 6) |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ( 58 6) |
| Mo in har ent trea vem sur y s es |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ( ) 143 |
0 | ( 3) 14 |
| Set tlem of ent res erv es |
0 | ( 1) 31 .37 |
31 .37 1 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Ch f pa rtic ipa tion nta in e xis ting bsi dia ang e o pe rce ge su ry ies com pan |
0 | 0 | ( 34 ) |
( 142 ) |
1.9 48 |
( 80 0) |
( 174 ) |
0 | ( 1.0 71 ) |
4.1 37 |
0 | ( 9.3 98 ) |
( 34 ) 5.5 |
| Se Ad jus ted ba lan at 3 0th tem ber 20 08 in a rda ce as p cco nce wit h IF RS |
24 .71 2 |
33 .35 5 |
11 2 |
1.7 92 |
( 23 .05 9) |
6.4 53 |
2.1 01 |
( 1.9 24 ) |
19 .31 6 |
64 .42 0 |
( 12 .86 6) |
11 9.6 46 |
23 4.0 58 |
| 0 | |||||||||||||
| Ad jus ted ba lan at 1st Ja 200 9 in dan wit h ce as nua ry ac cor ce IFR S |
24 .71 2 |
33 .37 3 |
13 7 |
1.6 77 |
( 27 .15 5) |
12 .30 0 |
2.1 32 |
( 7.2 68 ) |
22 .22 3 |
59 .35 7 |
( 12 .86 6) |
11 6.7 14 |
22 5.3 37 |
| Aju ste d to tal hen siv e in e fo r th erio d 1 /1- 30/ 9/2 009 com pre com e p afte r ta x |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 7 |
0 | 41 2 |
0 | 3.7 00 |
4.4 99 |
| Div ide nds id pa |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ( 3.0 82 ) |
( 3.0 82 ) |
| Re du dis trib utio e to ser ves n |
0 | 0 | 0 | 20 6 |
0 | 23 3 |
0 | 0 | 0 | ( 0) 44 |
0 | 0 | 0 |
| Ch f pa rtic ipa tion in e xis ting bsi dia nta ang e o pe rce ge su ry ies com pan |
0 | 0 | 1 | 0 | 0 | 0 | 0 | 28 | 0 | ( 60 0) |
0 | ( 94 3) |
( 1.5 14 ) |
| Ad jus ted ba lan at 3 0th Se ber 20 09 in a rda tem ce as p cco nce RS wit h IF |
24 .71 2 |
33 .37 3 |
13 8 |
1.8 84 |
( 27 .15 5) |
12 .53 4 |
2.1 32 |
( 6.8 53 ) |
22 .22 3 |
58 .72 9 |
( 12 .86 6) |
11 6.3 89 |
22 5.2 40 |
| Sh are Ca ita l p |
Sh are miu pre m |
Sta tut ory Re se rve |
Me rge r rib ble att uta res erv e |
Ta x res erv es |
Re lua tio va n of inv est nts me at fai alu r v e res erv e |
Re tai d ne rni s / ea ng ( los s) se |
Tre as ury Sh are s |
To tal |
|
|---|---|---|---|---|---|---|---|---|---|
| Ad jus ted ba lan at 1s t J 20 08 in rda ce as an ua ry ac co nc e wi th IFR S |
24 .71 2 |
11 7.2 03 |
1.4 20 |
( 30 .85 0) |
2.7 93 |
0 | ( 11 .01 4) |
( 86 3) |
10 3.4 02 |
| Aju ste d t ota l co reh siv e i fo r th eri od 1/ 1- mp en nco me e p 30 /9/ 20 08 af ter ta x ( ote 5) se e n |
0 | 0 | 0 | 0 | 0 | 0 | 95 1 |
0 | 95 1 |
| f s Inc in s ha ita l th h c ita liza tio ha rea se re ca p rou g ap n o re miu pre m |
51 .89 1 |
( 51 .89 1) |
0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Re du ctio f s ha ita l to of fse t p iou rs' los n o re ca p rev s y ea se s |
( 47 .83 9) |
0 | 0 | 0 | 0 | 0 | 47 .83 9 |
0 | 0 |
| f s Re du ctio ha ita l by tur nin h t ha reh old n o re ca p re g c as o s ers |
( ) 4.0 51 |
0 | 0 | 0 | 0 | 0 | 0 | ( ) 4.0 51 |
|
| Sh ita l in are ca p cre as e e xp en se s |
0 | ( 58 6) |
0 | 0 | 0 | 0 | 0 | 0 | ( 58 6) |
| Se of ttle nt me res erv es |
0 | ( 1) 31 .37 |
0 | 31 .37 1 |
0 | 0 | 0 | 0 | 0 |
| Mo nt in t sh ve me rea su ry are s |
0 | 0 | 0 | 0 | 0 | 0 | 0 | ( 54 ) |
( 54 ) |
| Ad jus ted ba lan at 30 th Se tem be r 2 00 8 i ord ce as p n a cc an ce wi th IFR S |
24 .71 2 |
33 .35 5 |
1.4 20 |
52 1 |
2.7 93 |
0 | 37 .77 7 |
( 7) 91 |
99 .66 1 |
| Ad jus ted ba lan at 1s t J 20 09 in rda ce as an ua ry ac co nc e S wi th IFR |
24 .71 2 |
33 .37 3 |
1.4 20 |
52 1 |
2.7 93 |
( 43 ) |
37 .32 6 |
( 91 7) |
99 .18 4 |
| Aju d t l co reh siv e i fo r th eri od 1/ 1- ste ota mp en nco me e p 30 /9/ 20 09 af ter ta x |
0 | 0 | 0 | 0 | 0 | 44 | ( 1.3 15 ) |
0 | ( 1.2 71 ) |
| Ch in s d to dis trib utio an ge re se rve ue n |
0 | 0 | 0 | 0 | 25 9 |
0 | ( 25 9) |
0 | 0 |
| Ad jus ted ba lan at 30 th Se tem be r 2 00 9 i ord ce as p n a cc an ce wi th IFR S |
24 .71 2 |
33 .37 3 |
1.4 20 |
52 1 |
3.0 51 |
1 | 35 .75 2 |
( 7) 91 |
97 .91 3 |
| 1/1-30/9/2009 1/1-30/9/2008 1/1-30/9/2009 1/1-30/9/2008 Cash flows from operating activities: Profit before tax 6.344 (13.665) (1.410) 187 Plus (less) adjustments for: Depreciation and amortization expenses 12.783 12.832 987 1.546 Provisions 634 2.948 41 64 Loss / (gain) from sale of fixed assets 180 102 0 (237) loss (gain) from disposal and valuation of investments 2.859 16.805 0 (552) Amortization of government grants (100) (110) 0 0 Income from participations 0 0 0 0 loss (gain) from participation in subsidiary company (1.269) (1.775) 0 (1.008) Debit interest and other related expenses (20) (535) 0 0 12.660 15.949 1.446 2.080 Plus / (less) adjustments for changes in working capital or 34.071 32.550 1.064 2.080 concerning operating activities: Increase) / decrease in inventories (Increase) / decrease in trade and other receivables 1.011 3.228 1.100 187 Decrease / (increase) in long term receivables (28.867) (13.984) 492 781 Increase / (decrease) in payables (less bank loans) (216) 354 (11) (0) (Less): 34.954 (31.579) 1.106 (14.860) Debit interest and other related expenses paid Income taxes paid (13.284) (15.625) (1.446) (2.109) Net cash in/out generated from operating activities (a) (8.112) (12.957) (415) (2.012) 19.557 (38.013) 1.891 (15.932) Cash flows from investing activities: Aqcuisitions of subsidiaries, affiliates, joint ventures and other investments* Purchase of treasury shares (19.331) (56.035) (100) (11.225) Purchase of tangible & intangible assets 0 (143) 0 (54) Proceeds from tangible and intangible assets sales (39.208) (35.254) 0 (339) Proceeds from sale of investments and securities 78 698 0 14.374 Proceeds from financial assets 14.272 25.159 1.720 3.476 Interest received 2 0 0 0 Proceeds from government grants 622 854 0 29 Dividends received 0 4 0 0 Net cash from in investing activities (b) 1.269 1.803 0 1.008 (42.297) (62.914) 1.621 7.267 Cash flows from financing activities Share capital increase expences 0 (586) 0 (586) Proceeds from / Repayment of borrowings 22.302 108.090 (3.402) 9.526 Change in finance lease liabilities 766 (2.180) 0 0 Dividends paid (3.793) (3.503) (29) (273) Board of Directors' fees (1.383) (611) 0 0 Net cash generated from financing activities (c) 17.893 101.209 (3.432) 8.666 Net increase / (decrease) in cash & cash equivalents (4.848) 281 80 1 (a)+(b)+(c) Cash & cash equivalents at beginning of period 38.386 30.842 152 363 Cash & cash equivalents at end of the period 33.538 31.123 232 364 |
CASH FLOW STATEMENT | GROUP | COMPANY | ||
|---|---|---|---|---|---|
| Board of Directors: | Terzopoulos Apostolos (President) Doumanoglou Panagiotis (Chief Excecutive Officer) Nanopoulos Dimitrios (Non executive member Member) Nikolaidis Petros (Non executive member Member) Paka Paraskevi (Non executive member Member) |
|---|---|
| Headquarters: | 2 Ermou Street , Athens Athens GR-105 63 Greece |
| S.A. Reg. Number: | 16226/06/Β/87/17 |
| Auditing Firm: | BDO CERTIFIED & REGISTERED AUDITORS A.E. 81 Patission Street & Heyden 8-10 Athens GR-104 34, Greece |
The Group of Companies AXON HOLDINGS S.A. is primarily operating in the following sectors: (a) the establishment, organization and operation of clinics and scientific centers equipped with advanced technology equipment as well as the provision of medical services of every nature, (b) the production and trade of defense information systems and technology, (c) the provision of stock exchange trading and financial services and (d) to the management,utilization and exploitation of real estate.
The headquarters of the Group's Parent Company AXON HOLDINGS S.A. (the Company or the Parent Company) are located at 2 Ermou Str, Athens.
The shares of the Parent Company are publicly traded in the Athens Stock Exchange (classified in the Medium and Small Capitalization Category).
The attached semi-annual consolidated and non-consolidated financial statements for the period ended 30/9/2009 (1/1-30/9/2009) have been prepared in accordance with the historical cost principle, with the exception of specific categories of tangible assets (buildings and land) and certain investments in shares and property that were valuated at fair value. Also, the aforementioned financial statements have been prepared on the basis of the going concern principle.
The attached semi-annual consolidated and non-consolidated financial statements for the period 1/1 - 30/9/2009 have been prepared in accordance with the International Financial Reporting Standards (IFRS) as published by the International Accounting Standards Board and have been adopted by the European Union as well as the Notes - Interpretations published by the Standards Interpretations Committee and were in use at 30st September 2009. Also, the interim financial statements in question are consistent with the provisions of I.A.S. 34 "Interim Financial Reporting" and there no Standards that have been implemented prior to the commencement date of their implementation, except of those that are reffered to the Note 2.3.
The interim financial statements for the period 1/1 - 30/9/2009 have been approved for publishing from the Board of Directors at 23th November 2009.
All figures in the interim financial statements are expressed in thousands of euro. It is noted that minor deviations are due to rounding up of figures.
The semi annual financial statements for the period ended 30/9/2009 (1/1-30/9/2009) have been prepared on the basis of the same accounting principles and methods followed for the preparation of the annual financial statements for the year ended 31st December 2008.
(Amounts are expressed in thousand Euros, unless otherwise stated)
Therefore, the attached interim financial statements should be read in relation with the annual thorough financial statements for the year ended 31st December 2008, uploaded to the Company's website, which contain a detailed analysis of the accounting principles, methods and estimates used as well as an analysis of the significant items of the financial statements.
The International Accounting Standards Board along with the Standards Interpretations Committee have issued a number of new financial reporting standards and interpretations, as well as amendments of existing standards, whose adoption is mandatory for the accounting periods beginning at 1stJanuary 2009 and thenceforth (unless mentioned otherwise bellow). The assessment of the Company's Management regarding the adoption effect of these new standards and interpretations is stated bellow:
IFRS 8 requires the provided segment information to be presented on the same basis as that used for internal reporting purposes. The information disclosed is the information that management uses in assessing the efficiency of each segment as well as the way financial and other resources are allocated to each segment. Management does not anticipate that the application of this standard will result in any material change in the manner that the segments are reported under IAS 14 "Segment Reporting". The Group and the Company are in the process of assessing possible effects of the above mentioned amendments.
In the amended edition of I.A.S. 23 the option of immediately expensing the borrowing costs has been removed. On the contrary, it requires an entity to capitalize borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset (one that takes a substantial period of time to get ready for use or sale, as defined in IAS 23) as part of the cost of that asset. The Company and the Group has implemented the aforementioned amendment starting from 1st July 2008. Additional information is offered in Note 11.
The amended IAS 1 requires the statement of changes in equity to comprise only transactions with the shareholders. As a result, a new statement of comprehensive income is introduced and the dividends to the shareholders will appear only in the statement of changes in equity or in the notes to the financial statements. The Group has chosen to present a Statement of Comprehensive Income. The Interim Condensed Financial Statements have been implemented according to the relevant adjusted notifications.
The amendment clarifies two issues: The Definition of "vesting condition", introducing the term "non vesting condition" for conditions other than service conditions and performance conditions. It also clarifies that the same accounting treatment applies to awards that are effectively cancelled by either the entity or the counterparty. The subject amendment is not applicable for the Group and the Company.
The amendment to IAS 32 requires certain puttable financial instruments and obligations
(Amounts are expressed in thousand Euros, unless otherwise stated)
arising on liquidation to be classified as equity if certain criteria are met. The amendment to IAS 1 requires disclosure of certain information relating to puttable instruments classified as equity. The Group and the Company are in the process of assessing possible effects of the above mentioned amendments.
The amendment to IFRS 1 allows an entity to determine the initial cost of investments in subsidiaries, jointly controlled entities or associates in its opening IFRS financial statements using a deemed cost, of either fair value or carrying amount under previous accounting practice. The amendment to IAS 27 requires all dividends from a subsidiary, jointly controlled entity or associate to be recognised in the income statement in the separate financial statement. The revision to IAS 27 will have to be applied prospectively. The aforementioned amendments are not applicable as the first time adoption date of the IFRS of the Group and the Company is the 1/1/2004.
The amended standard requires the effects of all tranSActions with non-controlling interests to be disclosured in equity if there is no change in control and these transactions will no longer result in goodwill or gains and losses. The standard also specifies the accounting when control is lost. The standard also specifies the accounting procedures when control is lost. Any remaining interest in the entity is re-valued at fair value, and a gain or loss is recognised in profit or loss. The Group and the Company have optionally implemented the amended IAS 27 from January 1st, 2009.
The most significant amendments of the revised IFRS 3 and IAS 27 are: a) the more extensive use of fair value through profit or loss; b) the recalculation of the participating interest when the control over an entity's operations is regained or lost; c) the direct recognition in equity of the effect of all the changes in the participating interest in controlled and not controlled entities, that do not lead to a loss of control; and d) the rendering of weight to the price that has been paid to the seller rather than the expenses that the buyer has incurred when gaining control over an entity, resulting in the costs that are associated with the acquisition and the changes to the initial price not be included in the combination cost but be often included in the income statement. The Group and the Company have optionally implemented the amended IFRS 3 & IAS 27 from January 1st, 2009.
The amendment of the IFRS 5 clarifies that all of a subsidiary's assets and liabilities are classified as held for sale if a partial sale plan results in loss of control. Relevant disclosure should be made for the subject subsidiary if the definition of a discontinued operation is met. A consequential amendment to IFRS 1 states that these amendments are applied prospectively from the first time adoption date of the IFRS. The amended IFRS 5 is not applicable for the Company and the Group.
The amendment of the IFRS 28 clarifies that an investment in an associate company is treated as a single asset for the purposes of impairment testing. Any impairment loss is not
(Amounts are expressed in thousand Euros, unless otherwise stated)
allocated to specific assets included within the investment, for example, goodwill. Reversals of impairment are recorded as an adjustment to the investment balance to the extent that the recoverable amount of the associate increases. The Group and the Company are in the process of assessing the effect of the amended IAS 28 and IAS 32.
This amendment clarifies that when discounted cash flows are used to estimate 'fair value less costs to sell', the same disclosure is required as when discounted cash flows are used to estimate 'value in use'. The amended IAS 36 is not applicable for the Company and the Group.
This amendment clarifies that a prepayment may only be recognised in the event that payment has been made in advance to obtaining right of access to goods or receipt of services. This practically means that when the entity has the right to access the goods or has received the services, then the payment will be recognized in profit or loss. The Group and the Company will implement the amended IAS 38 starting from 1st January 2009.
The changes in the amended IAS 19 are:
(a) Amendments to benefits plans that result in a reduction in benefits related to future services are accounted for as a curtailment, while an amendment that changes benefits attributable to past service gives rise to a negative past service cost if it results in a reduction in the present value of the defined benefit obligation.
(b) The definition of return on plan assets has been amended to state that plan administration costs are deducted in the calculation of return on plan assets only to the extent that such costs have been excluded from measurement of the defined benefit obligation.
(c) The distinction between short term and long term employee benefits will be based on whether benefits are due to be settled within or after 12 months of employee service being rendered.
(d) IAS 37, Provisions, contingent liabilities and contingent assets, requires contingent liabilities to be disclosed, not recognised. IAS 19 has been amended to be consistent.
The Group and the Company are in the process of assessing possible effects of the specific amendment.
The changes in the amended IAS 39 are:
(a) The amendment clarifies that a derivative may be either removed from, or included in the fair value through profit or loss category where it commences or ceases to qualify as a cash flow or net investment hedging instrument.
(b) The definition of financial asset or financial liability at fair value through profit or loss as it relates to assets held for trading is also amended. This clarifies that a financial asset or liability that is part of a portfolio of financial instruments managed together with evidence of an actual recent pattern of short-term profit taking is included in such a portfolio on initial recognition.
(c) The current guidance on designating and documenting hedges states that a hedging instrument needs to involve a party external to the reporting entity and cites a segment as an example of a reporting entity. This means that in order for hedge accounting to be applied at segment level, the requirements for hedge accounting are currently required to be met by the applicable segment. The amendment removes this requirement so that IAS 39 is consistent
(Amounts are expressed in thousand Euros, unless otherwise stated)
with IFRS 8, Operating segments which require disclosure for segments be based on information reported to the chief operating decision maker of the entity.
(d) When re-measuring the carrying amount of a debt instrument upon cessation of fair value hedge accounting, the amendment clarifies that a revised effective interest rate (calculated at the date fair value hedge accounting ceases) be used.
The amended IAS 39 is not applicable for the Group and the Company.
The amendment of the IAS 39 clarifies the procedures with which it should be made, in certain occasions, the rules that clarify whether a certain risk or part of the cash flow should be measured and recognized. The amendment of the IAS 39 is not applicable for the Group and the Company.
The amendment clarifies that assets and liabilities classified as held for trading in accordance with IAS 39 Financial Instruments: Recognition and Measurement are examples of current assets and liabilities respectively and are not automatically classified such in the balance sheet. The amended IAS 1 is not applicable for the Group and the Company.
The amendment of the IAS 16 provides for entities whose ordinary activities comprise renting and subsequently selling assets, to disclose proceeds from the sale of those assets as revenue and should transfer the carrying amount of the asset to inventories when the asset becomes available for sale. IAS 7 Statement of cash flows is also revised, to require cash flows arising from manufacturing, leasing or acquiring such items be classified as cash flows from operating activities. The amended IAS 16 and IAS 7 are not applicable for the Group and the Company.
The amendment of the IAS 27 clarifies that when a parent entity accounts for a subsidiary at fair value in accordance with IAS 39 in its separate financial statements, this treatment continues when the subsidiary is subsequently classified as held for sale according to IFRS 5. The amended IAS 27 is not applicable for the Group and the Company.
The amendment of the IAS 28 clarifies that where an investment in an associate company is accounted for in accordance with IAS 39 Financial instruments: recognition and measurement, only certain rather than all disclosure requirements in IAS 28 need to be made, in addition to disclosures required by IAS 32, Financial Instruments: Presentation and IFRS 7 Financial Instruments. The amended IAS 28, IAS 32 and IFRS 7 are not applicable for the Group and the Company.
The amendment to IAS 29 reflects the fact that a number of assets and liabilities are measured at fair value rather than historical cost. The amended IAS 29 is not applicable for the Group and the Company.
(Amounts are expressed in thousand Euros, unless otherwise stated)
This amendment of the IAS 31 clarifies that if a joint venture is accounted for at fair value, in accordance with IAS 39, in addition to the disclosure requirements by IAS 32, Financial instruments: Presentation, and IFRS 7, Financial instruments: Disclosures, only certain rather than all disclosure requirements in IAS 31 will apply. The amended IAS 31 is not applicable for the Group and the Company.
The amendment deletes references stating that there is "rarely, if ever" persuasive evidence to support an amortisation method for finite life intangible assets that results in a lower amount of accumulated amortisation than under the straight-line method. At the time being, the subject amendment will not affect the Company's operations as all intangible assets are amortized under the straight-line method.
Property that is under construction or development for future use as investment property is within the scope of IAS 40. Where the fair value model is applied, such property is, therefore, measured at fair value. However, where fair value of investment property under construction is not reliably measurable, the property is measured at cost until the earlier of the date construction is completed and the date at which fair value becomes reliably measurable. The amended IAS 40 is not applicable for the Group and the Company.
The amendment requires the use of a market-based discount rate where fair value calculations are based on discounted cash flows and the removal of the prohibition on taking into account biological transformation when calculating fair value. The amended IAS 41 is not applicable for the Group and the Company.
This amendment of IAS 20 clarifies that the benefit arising from a government loan granted with below-market interest rates is measured as the difference between the carrying amount in accordance with IAS 39 Financial instruments: Recognition and measurement, and the proceeds arising from the subject benefit as accounted for under IAS 20. The amended IAS 20 is not applicable for the Group and the Company.
IFRIC 15 provides guidance on how to determine whether an agreement for the construction of real estate is within the scope of IAS 11 'Construction Contracts' or IAS 18 'Revenue' and, accordingly, when revenue from such construction should be recognised. IFRIC 15 is not applicable for the Group and the Company.
IFRIC 17 provides guidance on the measurement of distribution of non-cash assets both when the liability is incurred and when the distribution is made. This includes both distributions of specific assets and more complex transactions, such as demergers. The subject guidance does not apply when the asset transferred is controlled by the same entity both before and after the transaction, as it is not relevant to distributions from a subsidiary to a parent, nor to transfers between subsidiaries accounted for as deemed distributions. It also does not apply if a parent distributes part of its investment in a subsidiary, creating a noncontrolling interest but retaining control. In this case the distribution is accounted for under
(Amounts are expressed in thousand Euros, unless otherwise stated)
IAS 27 (as amended in May, 2008). The Interpretation further clarifies that it only applies to distributions where all owners of the same class of equity instruments are treated equally. If an entity distributes assets to its equity shareholders who constitute both a parent company and non-controlling shareholders, the whole distribution is scoped out of the Interpretation because a proportion of the assets transferred are controlled by the same entity before and after the transfer. The Company is in the process of assessing the possible effect of the subject Interpretation.
This Interpretation specifies the requirements under the IFRS regarding agreements where an entity receives a tangible asset (or cash to construct such an asset) from a customer and this asset in turn is used to connect the customer to the trade network or to provide ongoing access to supply of goods/services (such as electricity, fuel or water). IFRIC 18 has not yet been adopted by the European Union.
The Group AXON HOLDINGS S.A. includes the following companies:
| COMPANY | REGISTERED OFFICE |
PRINCIPAL ACTIVITY |
PART/PATION PERCENTAGE |
CONS/DATION METHOD |
TYPE OF PART/PATION |
|---|---|---|---|---|---|
| AXON HOLDING | Athens | Holding | Parent | Full | - |
| Ι. Subsidiary companies | |||||
| EUROMEDICA S.A. | Athens | Medical services |
62,2% | Full | Direct & Indirect |
| ORASIS HELLENIC OPTHALMOLOGICAL CENTER S.A |
Athens | Medical services |
42,6% | Full | Indirect |
| S.K.D.S. BUSINESS CONSULTANTS S.A. | Athens | Consulting Services |
30,5% | Full | Indirect |
| IPPOKRATIS CENTER OF NUCLEAR MEDICINE S.A. |
Thessaloniki | Medical services |
37,3% | Full | Indirect |
| ASKLIPIIO HOSPITAL -RECOVERY REHABILITATION (Larisa) |
Larisa | Medical servises |
37,3% | Full | Indirect |
| YGEIA VOLOU MEDICAL DIAGNOSTIC CENTER VOLOS S.A. |
Volos | Medical services |
31,7% | Full | Indirect |
| MELAMBUS MEDICINE S.A. | Larisa | Medical services |
46,2% | Full | Indirect |
| THEOTOKOS MAIEYTIKI GYNEKOLOGIKI KLINIKI LARIS.A.S S.A. |
Larisa | Medical services |
48,5% | Full | Indirect |
| EUROMEDICA MULTIDIAGNOSTIC CENTER LARISA. S.A. |
Larisa | Medical services |
43,6% | Full | Indirect |
| PYLI AXIOU PRIVATE DIAGNOSTIC CENTER S.A. | Thessaloniki | Medical services |
46,2% | Full | Indirect |
| GENESIS MAIEYTIKI GYNECOLOGIKI KLINIKI THESSALONIKIS S.A. |
Thessaloniki | Medical services |
31,1% | Full | Indirect |
| EUROMEDICA MEDICAL ASSISTANCE CENTER SA |
Thessaloniki | Medical services |
35,5% | Full | Indirect |
| GENERAL CLINIC OF DODEKANISA S.A. | Rhodes | Medical services |
35,3% | Full | Indirect |
| GENIKI NOSILEFTIKI GENERAL SERVICES S.A. | Thessaloniki | Medical services |
31,7% | Full | Indirect |
1 January 2009 to 30th September 2009
| EURO PROCUREMENT S.A. | Athens | Trading of medical equipment and supplies |
62,2% | Full | Indirect |
|---|---|---|---|---|---|
| SONAK SA ELECTRONIC SYSTEMS & COMPUTER PROGRAMS |
Athens | Production of IT systems |
50,0% | Full | Direct |
| AXON SECURITIES | Athens | Financial Services |
40,0% | Full | Direct |
| EUROMEDICA S.A. REAL ESTATE | Athens | Real Estate services |
99,9% | Full | Direct & Indirect |
| EUROMEDICA GULF HOLDINGS S.A. | United Arab Emirates |
Holding company |
62,6% | Full | Direct & Indirect |
| DATA DESIGN S.A. | Athens | Production of IT systems |
49,8% | Full | Indirect |
| MURLOCH S.A. | Cyprus | Airplane business |
100,0% | Full | Indirect |
| EUROMEDICA GALATSIOY S.A. | Athens | Medical services |
62,2% | Full | Indirect |
| ALPHA NEFRODYNAMIKI SA. | Serres | Medical services |
29,2% | Full | Indirect |
| EUROMEDICA CRETE RECOVERY AND REHABILITATION CENTER S.A. |
Heraklion | Consulting Services |
31,1% | Full | Indirect |
| MAGNETIC TOMOGRAPHY VOLOY SA | Bolos | Medical services |
24,3% | Full | Indirect |
| PRIVATE DIAGNOSTIC LAB - MEDICAL S.A. (AXIAL TOMOGRAFY SERRES) |
Serres | Medical services |
29,2% | Full | Indirect |
| EUROMEDICA PALAIOU FALIROU S.A. | Athens | Medical services |
30,5% | Full | Indirect |
| YGEIA MAGNETIC DIAGNOSIS S.A. | Ptolemaida | Medical services |
30,5% | Full | Indirect |
| EUROMEDICA FINANCE Νο 1 S.A. | Luxembourgh | Financial Services |
62,2% | Full | Indirect |
| TOURISTIC ENTERPRISES W. MACEDONIA S.A. | Florina | Hospitality services |
61,9% | Full | Indirect |
| EGEFALOS PELOPONISOU S.A. | Athens | Management of medical units |
100,0% | Full | Direct |
| ARISTOTELEIO PRIVATE DIAGNOSTIC LABORATORY AXIAL TOMOGRAPHY IATRIKI S.A. |
Thessaloniki | Medical services |
32,4% | Full | Indirect |
| IONIA EUROMEDICA OF CORINTHOS S.A. | Korinthos | Medical services |
25,8% | Full | Indirect |
| MEDINET ALEXANDROUPOLIS S.A. | Alexandroupolis | Medical services |
30,5% | Full | Indirect |
| AROGI S.A. | Larisa | Medical services |
62,2% | Full | Indirect |
| APOKATASTASI S.A | Larisa | Medical services |
62,2% | Full | Indirect |
| EUROMEDICA EASTERN ATTICA PRIVATE MULTI-SPECIALTY DIAGNOSTIC CENTER IATRIKI S.A. |
Athens | Medical services |
44,7% | Full | Indirect |
| IONIOS GENERAL CLINIC S.A. (CORFU) | Corfu | Medical services |
40,0% | Full | Indirect |
1 January 2009 to 30th September 2009
| MEGARA PRIVATE MEDICAL DIAGNOSTIC LAB SA |
Elefsina | Medical services |
62,2% | Full | Indirect |
|---|---|---|---|---|---|
| IONIA PRIVATE MULTI-SPECIALTY DIAGNOSTIC CENTER MEDICAL S.A |
Elefsina | Medical services |
62,2% | Full | Indirect |
| IONIA NEFROLOGIKI S.A | Elefsina | Medical services |
30,5% | Full | Indirect |
| GALINOS MEDICAL DIAGNOSTIC TRIKALON SA | Trikala | Medical services |
29,2% | Full | Indirect |
| MULTI-DIAGNOSTIC CENTER PIERIAS IATRIKI S.A. |
Pieria | Medical services |
41,6% | Full | Indirect |
| PRIVATE NEUROPSYCHIATRIC CLINIC KASTALIA S.A. |
Katerini | Medical services |
31,1% | Full | Indirect |
| IPPOKRATIS - MULTI-SPECIALTY DIAGNOSTIC CENTER S.A. |
Nikaia | Medical services |
28,3% | Full | Indirect |
| IPPOKRATIS MAGNETIC TOMOGRAPHY S.A | Nikaia | Medical services |
24,0% | Full | Indirect |
| AXIAL TOMOGRAFOS N. IONIA S.A. | Bolos | Medical services |
24,9% | Full | Indirect |
| MEDICAL DIAGNOSIS OF LESVOS S.A. | Lesvos | Medical services |
25,5% | Full | Indirect |
| MEDINET KAVALAS PRIVATE DIAGNOSTOC CENTER S.A |
Kavala | Medical services |
21,2% | Full | Indirect |
| ΕUROMEDICA AROGI ACHAIAS S.A. | Athens | Medical services |
62,2% | Full | Indirect |
| ΕUROMEDICA LYDIA KAVALAS S.A. | Kavala | Medical services |
31,4% | Full | Indirect |
| ZOE-GENIKI THERAPEFTIKI PRIVATE CLINIC S.A. |
Thessaloniki | Medical services |
52,3% | Full | Indirect |
| EUROMEDICA ALBANIA HOLDINGS S.A. | Athens | Medical services |
62,6% | Full | Indirect |
| IONIA-EUROMEDICA PRIVATE POLYATREIO S.A. | Aspropirgos | Medical services |
30,5% | Full | Indirect |
| DIAGNOSTIC CENTER IKEDA LTD | Tirana | Medical services |
31,9% | Full | Indirect |
| PAGKRITIA HOLDINGS Mutual Funds | Heraklion, Crete |
Mutual Fund | 80,0% | Full | Direct |
| ΑΧΟΝ FINANCE S.A. | Athens | Financial Services |
60,0% | Full | Direct |
| PRIVATE DIAGNOSTIC LABORATORY EURODIAGNOSIS CORFU S.A. |
Corfu | Medical services |
23,3% | Full | Indirect |
| EUROMEDICA SERRES S.A. | Serres | Medical services |
29,2% | Full | Indirect |
| DIAGNOSTIC CENTER LARISA S.A. | Larisa | Medical services |
26,1% | Full | Indirect |
| NEUROLOGICAL PSYCHIATRIC CLINIC A. PISSALIDIS – A. KARIPIS S.A. |
Thessaloniki | Medical services |
31,1% | Full | Indirect |
| PRIVATE DIAGNOSTIC LABORATORY ALEXANDREIO S.A. |
Thessaloniki | Medical services |
30,5% | Full | Indirect |
| PRIVATE DIAGNOSTIC LABORATORY OF WESTERN THESSALONIKI S.A. |
Thessaloniki | Medical services |
26,1% | Full | Indirect |
| AXIAL DIAGNOSIS S.A. | Thessaloniki | Medical services |
62,2% | Full | Indirect |
| EUROMEDICA APOKATASTASI S.A. | Athens | Medical services |
31,1% | Full | Indirect |
| VOGIATZIS PRIVATE DIAGNOSTIC LABORATORY S.A. |
Didimoteixo | Medical services |
29,9% | Full | Indirect |
| PRIVATE DIAGNOSTIC LABORATORY EUROMEDICA TRIKALA S.A. |
Trikala | Medical services |
14,3% | Full | Indirect |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| KASTALIA ACHAIAS S.A. | Patra | Medical services |
15,6% | Full | Indirect |
|---|---|---|---|---|---|
| D.S. SIOVAS – RADIODIAGNOSTIC CENTER GREVENA |
Grevena | Medical services |
30,5% | Full | Indirect |
| ΙΙ . Associates | |||||
| EUROGENETIKI S.A. - MODEL CENTER OF RESEARCH AND APPLICATION OF MOLECULAR BIOLOGY |
Thessaloniki | Medical services |
24,9% | Equity method | Indirect |
| MEDITRON S.A. | Thessaloniki | Trading and service of medical machinery |
24,9% | Equity method | Indirect |
| DORMED HELLAS A.Ε. | Thessaloniki | Trading and service of medical machinery |
24,0% | Equity method | Indirect |
| MEDICAL DIAGNOSTIC LABORATORY MEDICINE KOZANIS SA |
Kozani | Medical services |
13,1% | Equity method | Indirect |
| MEDITREND S.A. | Athens | Trading and service of medical machinery |
31,1% | Equity method | Indirect |
| EUROMEDICA KARDITSAS S.A. | Karditsa | Medical services |
14,9% | Equity method | Indirect |
| .E. EUROHOSPITAL ADVISORY AND HOSPITAL FACILITY MANAGEMENT SA |
Athens | Management of medical units |
0,0% | Equity method | Indirect |
| EUROMEDICA WESTERN MACEDONIA-KOZANI S.A. |
Kozani | Medical services |
15,5% | Equity method | Indirect |
| EUROMEDICA COSMETIC PRIVATE POLYIATREIO S.A. |
Athens | Medical services |
22,7% | Equity method | Indirect |
| CENTRAL MEDICAL SERVICES S.A. | Larisa | Medical services |
17,7% | Equity method | Indirect |
The country in which the above-mentioned companies have their registered offices is Greece, except the subsidiary company EUROMEDICA FINANCE No 1 S.A., DIAGNOSTIC CENTER IKEDA LTD and the subsidiary company EUROMEDICA GULF HOLDINGS S.A. which are based in Luxemburg, Albania and United Arabic Emirates respectively.
At the preparation of the interim condensed financial statements for the period 1/1-30/9/2009, the comprehensive income of all the above subsidiaries and associates were included in the consolidated financial statements of the Group for the following periods:
| Companies | Period for which the companies were included in the consolidated financial statements of the current period |
Period for which the companies were included in the consolidated financial statements of the previous comparative period |
|---|---|---|
| AXON HOLDING | ||
| Ι. Subsidiary companies | ||
| EUROMEDICA S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| ORASIS HELLENIC OPTHALMOLOGICAL CENTER S.A | 1/1-30/9/2009 | 1/1-30/9/2008 |
| IPPOKRATIS CENTER OF NUCLEAR MEDICINE S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
1 January 2009 to 30th September 2009 (Amounts are expressed in thousand Euros, unless otherwise stated)
| YGEIA VOLOU MEDICAL DIAGNOSTIC CENTER VOLOS S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
|---|---|---|
| MELAMBUS MEDICINE S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| THEOTOKOS MAIEYTIKI GYNEKOLOGIKI KLINIKI LARIS.A.S S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| EUROMEDICA MULTIDIAGNOSTIC CENTER LARISA. S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| PYLI AXIOU PRIVATE DIAGNOSTIC CENTER S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| GENESIS MAIEYTIKI GYNECOLOGIKI KLINIKI THESSALONIKIS S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| EUROMEDICA AROGI MEDICAL CENTER APOKATASTASI S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| GENERAL CLINIC OF DODEKANISA S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| EURO PROCUREMENT S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| SONAK SA ELECTRONIC SYSTEMS & COMPUTER PROGRAMS |
1/1-30/9/2009 | 1/1-30/9/2008 |
| AXON SECURITIES | 1/1-30/9/2009 | 1/1-30/9/2008 |
| DATA DESIGN S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| PRIVATE DIAGNOSTIC CENTER MAGNETIC TOMOGRAPHY VOLOS S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| PRIVATE DIAGNOSTIC LAB - MEDICAL S.A. (AXIAL TOMOGRAFY SERRES) |
1/1-30/9/2009 | 1/1-30/9/2008 |
| EUROMEDICA PALAIOU FALIROU S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| YGEIA MAGNETIC DIAGNOSIS S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| EUROMEDICA FINANCE Νο 1 S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| TOURISTIC ENTERPRISES W. MACEDONIA S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| EGEFALOS PELOPONISOU S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| ARISTOTELEIO PRIVATE DIAGNOSTIC LABORATORY AXIAL TOMOGRAPHY IATRIKI S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| IONIA EUROMEDICA OF CORINTHOS S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| MEDINET ALEXANDROUPOLIS S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| AROGI S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| APOKATASTASI S.A | 1/1-30/9/2009 | 1/1-30/9/2008 |
| EUROMEDICA EASTERN ATTICA PRIVATE MULTI SPECIALTY DIAGNOSTIC CENTER IATRIKI S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| IONIOS GENERAL CLINIC S.A. (CORFU) | 1/1-30/9/2009 | 1/1-30/9/2008 |
| MEGARA PRIVATE MEDICAL DIAGNOSTIC LAB SA | 1/1-30/9/2009 | 1/1-30/9/2008 |
| IONIA PRIVATE MULTI-SPECIALTY DIAGNOSTIC CENTER MEDICAL S.A |
1/1-30/9/2009 | 1/1-30/9/2008 |
1 January 2009 to 30th September 2009
| IONIA NEFROLOGIKI S.A | 1/1-30/9/2009 | 1/1-30/9/2008 |
|---|---|---|
| GALINOS MEDICAL DIAGNOSTIC TRIKALON SA | 1/1-30/9/2009 | 1/1-30/9/2008 |
| MULTI-DIAGNOSTIC CENTER PIERIAS IATRIKI S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| PRIVATE NEUROPSYCHIATRIC CLINIC KASTALIA S.A. | 1/1-30/9/2009 | 1/3-30/9/2008 |
| IPPOKRATIS - MULTI-SPECIALTY DIAGNOSTIC CENTER S.A. |
1/1-30/9/2009 | 1/2-30/9/2008 |
| IPPOKRATIS MAGNETIC TOMOGRAPHY S.A | 1/1-30/9/2009 | 1/2-30/9/2008 |
| AXIAL TOMOGRAFOS N. IONIA S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| IONIOS GENERAL CLINIC S.A. (CORFU) | 1/1-30/9/2009 | 1/1-30/9/2008 |
| MEDINET KAVALAS PRIVATE DIAGNOSTOC CENTER S.A | 1/1-30/9/2009 | 1/1-30/9/2008 |
| ΕUROMEDICA AROGI ACHAIAS S.A. | 1/1-30/9/2009 | 30/9/2008 |
| ΕUROMEDICA LYDIA KAVALAS S.A. | 1/1-30/9/2009 | 30/9/2008 |
| ZOE-GENIKI THERAPEFTIKI PRIVATE CLINIC S.A. | 1/1-30/9/2009 | 30/9/2008 |
| EUROMEDICA ALBANIA HOLDINGS S.A. | 1/1-30/9/2009 | 1/4-30/9/2008 |
| IONIA PRIVATE MULTI-SPECIALTY DIAGNOSTIC CENTER MEDICAL S.A |
1/1-30/9/2009 | 1/4-30/9/2008 |
| DIAGNOSTIC CENTER IKEDA LTD | 1/1-30/9/2009 | 1/5-30/9/2008 |
| ΑΧΟΝ MANAGEMENT S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| ΑΧΟΝ FINANCE S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| PRIVATE DIAGNOSTIC LABORATORY EURODIAGNOSIS CORFU S.A. |
1/1-30/9/2009 | 1/1-30/9/2008 |
| EUROMEDICA SERRES S.A. | 1/1-30/9/2009 | 26/6-30/9/2008 |
| DIAGNOSTIC CENTER LARISA S.A. | 1/1-30/9/2009 | 15/9-30/9/2008- |
| NEUROLOGICAL PSYCHIATRIC CLINIC A. PISSALIDIS – A. KARIPIS S.A. |
1/1-30/9/2009 | 22/8-30/9/2008 |
| PRIVATE DIAGNOSTIC LABORATORY ALEXANDRIO S.A. | 1/1-30/9/2009 | 25/9-30/9/2008 |
| PRIVATE DIAGNOSTIC LABORATORY OF WESTERN THESSALONIKI S.A. |
1/1-30/9/2009 | 25/9-30/9/2008 |
| AXIAL DIAGNOSIS S.A. | 1/1-30/9/2009 | - |
| EUROMEDICA APOKATASTASI S.A. | 1/1-30/9/2009 | - |
| VOGIATZIS PRIVATE DIAGNOSTIC LABORATORY S.A. | 1/1-30/9/2009 | - |
| S.K.D.S. BUSINESS CONSULTANTS S.A. | 1/1-30/9/2009 | - |
| ASKLIPIIO HOSPITAL -RECOVERY REHABILITATION (Larisa) | 1/1-30/9/2009 | - |
| Euromedica Reak Estate | 1/1-30/9/2009 | - |
| PRIVATE DIAGNOSTIC LABORATORY EUROMEDICA TRIKALA S.A. |
1/2-30/9/2009 | - |
| D.S. SIOVAS – RADIODIAGNOSTIC CENTER GREVENA | 1/2-30/9/2009 | - |
| KASTALIA ACHAIAS S.A. | 1/4-30/9/2009 | - |
| GENIKI NOSILEFTIKI GENERAL SERVICES S.A. | 23/4-30/9/2009 | - |
1 January 2009 to 30th September 2009 (Amounts are expressed in thousand Euros, unless otherwise stated)
| EUROMEDICA GULF HOLDINGS S.A. | 30/6-30/9/2009 | - |
|---|---|---|
| EUROMEDICA GALATSIOY S.A. | 1/7-30/9/2009 | - |
| EUROMEDICA CRETE RECOVERY AND REHABILITATION CENTER S.A. |
1/7-30/9/2009 | - |
| ALPHA NEFRODYNAMIKI SA. | 20/8-30/9/2009 | - |
| ΙΙ . Associates | ||
| EUROGENETIKI S.A. - MODEL CENTER OF RESEARCH AND APPLICATION OF MOLECULAR BIOLOGY |
1/1-30/9/2009 | 1/1-30/9/2008 |
| MEDITRON S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| DORMED HELLAS S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| MEDICINE DIAGNOSTIC LABORATORY KOZANI S.A. | 1/1-30/9/2009 | 1/1-30/9/2008 |
| MEDITREND S.A. | 1/1-30/9/2009 | 1/4-30/9/2008 |
| PRIVATE POLYDIAGNOSTIC CENTER KARDITS.A. S.A. | 1/1-30/9/2009 | 30/6-30/9/2008 |
| EUROMEDICA WESTERN MACEDONIA-KOZANI S.A. | 1/1-30/9/2009 | - |
| EUROMEDICA COSMETIC PRIVATE POLYIATREIO S.A. | 1/4-30/9/2009 | ‐ |
| CENTRAL MEDICAL SERVICES S.A. | 30/6-30/9/2009 | ‐ |
In the closing year the participating interests of the Group in subsidiaries and associates changed in the following way:
participation in medical centers in the United Arab Emirates and generally in the countries of the Arabian Peninsula.
of the company is mainly its participation in medical centers in the United Arab Emirates and the countries of the Arabian Peninsula.
(Amounts are expressed in thousand Euros, unless otherwise stated)
paid for buy the Group EUROMEDICA S.A., consequently participation percentage of the parent company in the afformentioned subsidiary on 30/9/2009 amounts to 99,6% (62,0% for the Group).
(Amounts are expressed in thousand Euros, unless otherwise stated)
At the end of the prior year equity of the subsidiary company of the Group EGEFALOS PELOPONNISOU GENERAL AND THERAPEUTIC RESEARCH CENTER SA had become smaller than the 10.0% of the outstanding share capital thereby the provisions of paragraph 1 of Article 48 of Law 2190/20 were applicable. By 18/9/2009 Unsolicited
(Amounts are expressed in thousand Euros, unless otherwise stated)
General Meeting of shareholders decision was taken to liquidate the company whith liquidation starting date 18/9/2009. The contribution of the assets of that subsidiary in the consolidated total assets and turnover is not material.
The management of the Group proceeds in estimates, assumptions, judgements and evaluations in order to select the most suitable accounting principles and rules concerning the future development of events and of the in progress conditions and transactions. These estimates, judgements and assumptions are re-examined periodically so that they correspond to the current facts and reflect the current risks and are based on the previous experience of the Management of the Group concerning the nature and the level of the relative transactions and facts.
The basic estimates and evaluative judgements regarding data, the development of which could influence the financial statements for the next twelve months are as following:
The Group carries out the required by the provisions of the IFRS impairment test of the of goodwill arising from mergers or acquisitions of companies whose control is assumed or influenced in an essential way, at least annually. Part of the process of the determination of the recoverable amount of each investment, is the calculation of the value in use of the cash flow generating units in which the relative goodwill has been allocated. The calculation of the value in use requires the estimation of the forecasted (future) cash flows of each cash flow generating unit, as well as the selection of an appropriate discount factor of these in present.
The Group uses the provisions of IAS 11, regarding recognition of income from the construction of projects and advanced technology services relevant to defense systems and technology, by using the percentage of completion method. According to this method, at every balance sheet date, the cost that has been incurred for the implementation of contracts in progress is compared to the total budgeted cost for the completion of each contract in order to determine the percentage of completion at the time. The cumulative effects of potential revisions and re-estimates of the budgeted cost of the projects as well as the contractual revenue are recorded during the financial years that these occur. The budgeted cost and the contractual revenue for each project construction and advanced-technology services contract is defined after evaluating proceedings and they are reviewed and reestimated at each balance sheet date.
The Group impairs the value of trade receivables when there is evidence or indications that the collection of each receivable in whole or up to a percentage is not feasible. The Management of the Group proceeds to temporary revaluation of the formulated provision for doubtful debts in relation with the credit policy and data from the Group's Law Department, which arises from processing past data and recent developments of each case.
The provision for income tax under IFRS 12 is calculated by an estimate of payable taxes to tax authorities and includes the current income tax for each use, and provision for additional taxes that might arise in future tax audits. In order for the relative provision of the Company for income taxes to be determined, significant understanding of the above is required. The final statement of income taxes may differ from the amounts which are recorded in the
financial statements of the Company and these differences will affect the income tax and provisions for deferred taxes.
Up to the end of the third semester of 2008 the Group recognized the tax liabilities emerging from tax audits if unaudited fiscal years, including liabilities of the Parent Company, its subsidiaries and its associates, after the completion of the audit and the finalization of the additional tax amounts. At 31/12/2008 the Management of the Group decided to change the above accounting policy adopted for tax unaudited fiscal years to a policy of conducting adequate provisions per annum covering all estimated tax differences that may arise in a future tax audit. The Management believes that with this change, although the provision for tax unaudited fiscal years is not easy because of the existence of uncertainties in several tax provisions that create difficulties in defining the relevant provision, will enhance the completeness of financial statements prepared. As a consequence, the Management, based on findings of recently carried out tax audits, proceeded to the identification of the total additional tax burden and its recognition in the finacial statements of the respective years that should be charged.
For the reform of the affected items in already published previous years financial statements, the Company has retroactively applied the provisions of IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".
Furthermore, at the end of the closing period the fair values of the assets, of the liabilities, as well as the goodwill that has been derived from the acquisition of the new subsidiaries companies have been finalized. As a consequence, the statement of the financial position, the statement of the comprehensive Income and the cash flow statement for the period 1/1- 30/9/2008 and for the period ended 31st December 2008 have been reformed.
From the change in the accounting policy for tax anaudited fiscal years as long as from the finalisation of the goodwill of the new subsidiaries companies, the Financial statements of the period 1/1-30/9/2008 as well as for the period ended 31st December 2008 were reformed as follows:
5.1.1 Period 1/1–30/9/2008 – Group's Statement Financial Position: The items of the Financial Position of the Group for the period ended 30th September 2008, were reformed as follows:
| STATEMENT OF FINANCIAL POSITION | Balance at 30/9/2008 as previously published |
Correction from the finalization of goodwill |
Correction from the change of the tax unautited year |
Reformed balance at 30/9/2008 |
|---|---|---|---|---|
| ASSETS | ||||
| Non-Current Assets: | ||||
| Tangible assets | 365.073 | (17.603) | 0 | 347.470 |
| Intangible assets | 3.692 | 1.564 | 0 | 5.257 |
| Goodwill | 136.629 | (11.418) | 0 | 125.211 |
| Investments in associates | 6.268 | 0 | 0 | 6.268 |
| Available for sale investments | 55.564 | 0 | 0 | 55.564 |
| Investment property | 961 | 29.571 | 0 | 30.531 |
| Non current receivables | 16.617 | 0 | 0 | 16.617 |
| Deferred income taxes | 1.186 | 257 | 0 | 1.443 |
| Total Non-Current Assets: | 585.992 | 2.370 | 0 | 588.362 |
| Current Assets: | ||||
| Inventories | 25.612 | 7 | 0 | 25.619 |
| Customers and other receivables | 211.235 | (2.621) | 0 | 208.614 |
| Financial assets at fair value through income statement | 2.858 | 0 | 0 | 2.858 |
| Cash and cash equivalents | 31.863 | (740) | 0 | 31.123 |
| Total current assets | 271.567 | (3.353) | 0 | 268.214 |
| TOTAL ASSETS | 857.559 | (983) | 0 | 856.576 |
| EQUITY AND LIABILITIES Equity |
||||
| Share capital | 24.712 | 0 | 0 | 24.712 |
| Premium on capital stock | 64.726 | (31.371) | 0 | 33.355 |
| Reserves | (15.308) | 20.098 | 0 | 4.791 |
| Accumulated profits (deficit) | 54.343 | 12.055 | (1.978) | 64.420 |
| Treasury shares | (12.866) | 0 | 0 | (12.866) |
| Total Equity attributable to Group shareholders | 115.607 | 782 | (1.978) | 114.411 |
| Minority interests | 122.613 | (1.387) | (1.579) | 119.646 |
| Total Equity | 238.220 | (605) | (3.557) | 234.058 |
| LIABILITIES Non-Current Liabilities |
||||
| Loans | 300.186 | 1.791 | 0 | 301.976 |
| Provision for staff retirement indemnities | 5.943 | 112 | 0 | 6.055 |
| Other provisions | 0 | 0 | 3.557 | 3.557 |
| Deferred income taxes | 27.885 | 1.535 | 0 | 29.419 |
| Grants for investments in fixed assets | 2.858 | 0 | 0 | 2.858 |
| Other long term obligations | 1.163 | 0 | 0 | 1.163 |
| Non-Current Liabilities | 338.034 | 3.438 | 3.557 | 345.029 |
| Current Liabilities | ||||
| Suppliers and other current liabilities | 186.033 | (161) | 0 | 185.872 |
| Short-term loans | 73.105 | 326 | 0 | 73.431 |
| Income taxes payable | 22.168 | (3.981) | 0 | 18.187 |
| Total current liabilities | 281.305 | (3.816) | 0 | 277.489 |
| Total Liabilities | 619.339 | (378) | 3.557 | 622.518 |
| TOTAL EQUITY AND LIABILITIES | 857.559 | (983) | 0 | 856.576 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
5.1.2 Period 1/1 – 30/9/2008 – Group's statement of comprehensive income: The items of the statement of the comprehensive Income of the Group for the period 1/1–30/9/2008 were reformed as follows:
| Balance at 30/9/2008 as previously published |
Correction from the finalization of goodwill |
Correction from the change of the tax unautited year |
Reformed balance at 30/9/2008 |
|
|---|---|---|---|---|
| STATEMENT OF COMPREHENSIVE INCOME | ||||
| Sales | 187.000 | 0 | 0 | 187.000 |
| Minus: Cost of goods sold | (149.575) | (899) | 0 | (150.474) |
| Gross profit | 37.425 | (899) | 0 | 36.526 |
| Other operating income | 3.469 | (33) | 0 | 3.436 |
| 40.894 | (932) | 0 | 39.961 | |
| Administrative expenses | (19.569) | 100 | 0 | (19.468) |
| Research and development expenses | (111) | 0 | 0 | (111) |
| Distribution expenses | (1.404) | 1 | 0 | (1.403) |
| Other operating expenses | (2.310) | (1) | (20) | (2.332) |
| Operating results | 17.500 | (833) | (20) | 16.647 |
| Financing cost | (15.948) | (1) | 0 | (15.949) |
| Results of ordinary activities | 3.328 | (834) | (20) | 698 |
| Income from Investments | (14.676) | 313 | 0 | (14.363) |
| Results before income taxes | (13.124) | (521) | (20) | (13.665) |
| Income taxes | 1.737 | 1.462 | (1.334) | 1.864 |
| Results after income taxes | (11.387) | 941 | (1.355) | (11.801) |
| Attributable to: | ||||
| - Owners of the parent | (8.412) | 793 | (569) | (8.188) |
| - Minority interests | (2.976) | 148 | (786) | (3.613) |
| Comprehensive income after taxes: | ||||
| Revaluation of investments at fair value | (4.232) | 0 | 0 | (4.232) |
| Income tax on other total comprehensive income | 3.220 | 0 | 0 | 3.220 |
| Total other comprehensive income after tax | (1.012) | 0 | 0 | (1.012) |
| Aggregated other comprehensive income after tax | (12.399) | 941 | (1.355) | (12.813) |
| Attributable to: | ||||
| - Owners of the parent | (9.250) | 793 | (569) | (9.026) |
| - Minority interests | (3.150) | 148 | (786) | (3.788) |
| Earnings per share (€ per share) | ||||
| Basic | (0,2198) | (0,2140) |
5.1.3 Period 1/1-30/9/2008 – Group Cash Flow Statement: The items of the Cash Flow Statement of the Group for the period 1/1-30/9/2008 were reformed as follows:
| CASH FLOW STATEMENT | Balance at 30/9/2008 as previously published |
Effect finalization of goodwill |
Effect of change in accounting policy regarding unaudited fiscal years' tax |
Adjusted balances at 30/9/2008 |
|---|---|---|---|---|
| Cash flow from operating activities: | ||||
| Earnings / (loss) before taxes | (13.124) | (521) | (20) | (13.665) |
| Plus (less) adjustments for: | ||||
| Depreciation and amortisation expenses | 11.900 | 932 | 0 | 12.832 |
| Provisions | 2.927 | 0 | 20 | 2.948 |
| Loss / (gain) from disposal of fixed assets | 96 | 6 | 0 | 102 |
| Loss (gain) on disposal of investments and valuation |
16.824 | (19) | 0 | 16.805 |
| Depreciation of fixed assets investment grants | (110) | 0 | 0 | (110) |
| Income from participations | (1.775) | 0 | 0 | (1.775) |
| Loss / (gain) from participations in associates | (535) | 0 | 0 | (535) |
| Debit interest and other related expenses | 15.948 | 1 | 0 | 15.949 |
| 32.150 | (187) | 0 | 31.964 | |
| Plus / (less) adjustments for changes in working capital or conserning operating activities: |
||||
| Increase) / decrease in inventories | 3.228 | 0 | 0 | 3.228 |
| (Increase) / decrease in trade and other receivables |
(13.867) | (117) | 0 | (13.984) |
| Decrease / (increase) of long term receivables | 354 | 0 | 0 | 354 |
| Increase / (decrease) in payables (less loans) | (31.205) | (374) | 0 | (31.579) |
| (Less): | 0 | |||
| Debit interest and other related expenses paid | (15.624) | (1) | 0 | (15.625) |
| Income taxes paid | (13.026) | 69 | 0 | (12.957) |
| Net cash in/out generated from operating activities (a) |
(37.990) | (609) | 0 | (38.599) |
| Cash flows from investing activities:: | ||||
| Aqcuisitions of subsidiaries, affiliates, joint ventures and other investments |
(55.355) | (681) | 0 | (56.035) |
| Purchase of treasury shares | (143) | 0 | 0 | (143) |
| Purchase of tangible & intangible assets | (35.955) | 701 | 0 | (35.254) |
| Proceeds from tangible and intangible assets sales |
698 | 0 | 0 | 698 |
| Proceeds from sales of financial assets and investments |
25.159 | 0 | 0 | 25.159 |
| Interest received | 854 | 0 | 0 | 854 |
| Proceeds from government grants | 4 | 0 | 0 | 4 |
| Dividends received | 1.803 | 0 | 0 | 1.803 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Net cash used in investing activities (b) | (62.935) | 21 | 0 | (62.914) |
|---|---|---|---|---|
| 0 | ||||
| Cash flows from financing activities | 0 | |||
| Share capital increase expences | (586) | 0 | 0 | (586) |
| Proceeds from / Repayment of borrowings | 108.839 | (750) | 0 | 108.090 |
| Repayment of finance lease liabilities | (2.194) | 14 | 0 | (2.180) |
| Dividends paid | (3.503) | 0 | 0 | (3.503) |
| Board of Directors' fees | (611) | 0 | 0 | (611) |
| Net cash generated from financing activities (c) |
101.944 | (149) | 0 | 101.795 |
| Net increase / (decrease) in cash & cash equivalents (a)+(b)+(c) |
1.019 | (738) | 0 | 281 |
| Cash & cash equivalents at the beginning of the period |
30.843 | (1) | 0 | 30.842 |
| Cash & cash equivalents at end of the period | 31.863 | (740) | 0 | 31.123 |
5.2.1 Period 1/1–30/9/2008 – Company's Statement of Financial Position: The items of the Financial Position of the Company for the period ended 30th September 2008, were reformed as follows:
| STATEMENT OF FINANCIAL POSITION | Balance at 30/9/2008 as previously published |
Correction from the finalization of goodwill |
Correction from the change of the tax unautited year |
Reformed balance at 30/9/2008 |
|---|---|---|---|---|
| ASSETS | ||||
| Non-Current Assets: | ||||
| Tangible assets | 33.545 | (28.553) | 0 | 4.993 |
| Intangible assets | 26 | 1.267 | 0 | 1.293 |
| Goodwill | 12.177 | (11.656) | 0 | 521 |
| Investments in associates | 106.364 | 0 | 0 | 106.364 |
| Available for sale investments | 6.649 | 0 | 0 | 6.649 |
| Investment property | 6.610 | 28.771 | 0 | 35.381 |
| Non current receivables | 6 | 0 | 0 | 6 |
| Total Non-Current Assets: | 165.377 | (10.171) | 0 | 155.206 |
| Current Assets: | ||||
| Inventories | 931 | 0 | 0 | 931 |
| Customers and other receivables | 2.189 | 0 | 0 | 2.189 |
| Financial assets at fair value through income statement | 2.849 | 0 | 0 | 2.849 |
| Cash and cash equivalents | 364 | 0 | 0 | 364 |
| Total current assets | 6.333 | 0 | 0 | 6.333 |
| 0 | ||||
| TOTAL ASSETS | 171.710 | (10.171) | 0 | 161.539 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Equity | ||||
|---|---|---|---|---|
| Share capital | 24.712 | 0 | 0 | 24.712 |
| Premium on capital stock | 64.726 | (31.371) | 0 | 33.355 |
| Reserves | (15.382) | 20.115 | 0 | 4.733 |
| Accumulated profit/(deficit) | 33.306 | 5.263 | (792) | 37.778 |
| Treasury shares | (917) | 0 | 0 | (917) |
| Equity | 106.446 | (5.992) | (792) | 99.662 |
| LIABILITIES | ||||
| Non-Current Liabilities | ||||
| Loans | 35.960 | 0 | 0 | 35.960 |
| Provision for staff retirement indemnities | 153 | 401 | 0 | 554 |
| Other provisions | 0 | 0 | 792 | 792 |
| Deferred income taxes | 8.393 | (768) | 0 | 7.625 |
| Non-Current Liabilities | 44.506 | (368) | 792 | 44.930 |
| Current Liabilities | ||||
| Suppliers and other current liabilities | 4.816 | 0 | 0 | 4.816 |
| Short-term loans | 11.495 | 0 | 0 | 11.495 |
| Income taxes payable | 4.447 | (3.811) | 0 | 636 |
| Total current liabilities | 20.758 | (3.811) | 0 | 16.947 |
| Total Liabilities | 65.264 | (4.179) | 792 | 61.877 |
| TOTAL EQUITY AND LIABILITIES | 171.710 | (10.171) | 0 | 161.539 |
5.2.2 Period 1/1 – 30/9/2008 – Company's statement of comprehensive income: The items of the statement of the comprehensive Income of the Company for the period 1/1– 30/9/2008 were reformed as follows:
| Balance at 30/9/2008 as previously published |
Correction from the finalization of goodwill |
Correction from the change of the tax unautited year |
Reformed balance at 30/9/2008 |
|
|---|---|---|---|---|
| STATEMENT OF COMPREHENSIVE INCOME | ||||
| Sales | 5.417 | 0 | 0 | 5.417 |
| Minus: Cost of goods sold | (3.561) | (985) | 0 | (4.545) |
| Gross profit | 1.856 | (985) | 0 | 872 |
| Other operating income | 9.372 | (8.817) | 0 | 555 |
| 11.228 | (9.802) | 0 | 1.427 | |
| Administrative expenses | (692) | 0 | 0 | (692) |
| Distribution expenses | (6) | (1) | (20) | (27) |
| Operating results | 10.531 | (9.803) | (20) | 707 |
| Financing cost | (2.080) | 0 | 0 | (2.080) |
| Results of ordinary activities | 8.450 | (9.803) | (20) | (1.373) |
| Income from Investments | 1.266 | 294 | 0 | 1.560 |
| Results before income taxes | 9.717 | (9.510) | (20) | 187 |
| Income taxes | (2.567) | 3.517 | (186) | 764 |
| Results after income taxes | 7.150 | (5.992) | (206) | 951 |
| Distributed to: | ||||
| - Owners of the parent | 7.150 | (5.992) | (206) | 951 |
| - Minority interests | 0 | 0 | 0 | 0 |
| Comprehensive income after taxes: Total tax income of the other comprehensive income |
0 | 0 | 0 | 0 |
| Aggregated tax income of other comprehensive income | 7.150 | (5.992) | (206) | 951 |
| Distributed to: - Owners of the parent - Minority interests |
7.134 0 |
(6.995) 0 |
(137) 0 |
2 0 |
|
|---|---|---|---|---|---|
| Earnings per share (€ per share) Basic |
0,1773 | 0,0236 |
5.2.3 Period 1/1-30/9/2008 – Company's Cash Flow Statement: There has not been any reformation of the items of the Company's Cash Flow Statement for the period 1/1- 30/9/2008.
| CASH FLOW STATEMENT | Balance at 30/9/2008 as previously published |
Correction from the finalization of goodwill |
Correction from the change of the tax unautited year |
Reformed balance at 30/9/2008 |
|---|---|---|---|---|
| Cash flow from operating activities: | ||||
| Earnings / (loss) before taxes | 9.717 | (9.510) | (20) | 187 |
| Plus (less) adjustments for: | ||||
| Depreciation and amortisation expenses | 562 | 985 | 0 | 1.546 |
| Provisions | 44 | 0 | 20 | 64 |
| Loss / gain from disposal of fixed assets | (8.792) | 8.554 | 0 | (237) |
| Loss / gain from disposal and revaluation of investments |
(552) | 0 | 0 | (552) |
| Income from participations | (1.008) | 0 | 0 | (1.008) |
| Debit interest and other related expenses | 2.080 | 0 | 0 | 2.080 |
| 2.051 | 29 | 0 | 2.080 | |
| Plus / (less) adjustments for changes in working capital or operating activities accounts: |
||||
| Increase) / decrease in inventories | 187 | 0 | 0 | 187 |
| (Increase) / decrease in trade and other receivables |
781 | 0 | 0 | 781 |
| Increase / (decrease) in payables (less loans) | (14.860) | 0 | 0 | (14.860) |
| (Minus): | 0 | |||
| Debit interest and other related expenses paid |
(2.109) | 0 | 0 | (2.109) |
| Income taxes paid | (2.012) | 0 | 0 | (2.012) |
| Net cash (used in) / generated from operating activities (a) |
(15.962) | 29 | 0 | (15.932) |
| Cash flows from investing activities:: | ||||
| Aqcuisitions of subsidiaries, affiliates, joint ventures and other investments |
(11.225) | 0 | 0 | (11.225) |
| Purchase of treasury shares | (54) | 0 | 0 | (54) |
| Purchase of tangible & intangible assets | (339) | 0 | 0 | (339) |
| Proceeds from tangible and intangible assets sales |
14.403 | (29) | 0 | 14.374 |
| Proceeds from financial assets and | 3.476 | 0 | 0 | 3.476 |
| investments sales Interest received |
29 | 0 | 0 | 29 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Dividents | 1.008 | 0 | 0 | 1.008 |
|---|---|---|---|---|
| Net cash used in investing activities (b) | 7.297 | (29) | 0 | 7.267 |
| Cash flows from financing activities | ||||
| Share capital increase expences | (586) | 0 | (586) | |
| Proceeds from / Repayment of borrowings | 9.526 | 0 | 0 | 9.526 |
| Dividends paid | (273) | 0 | 0 | (273) |
| Net cash generated from / (used in ) financing activities (c) |
8.666 | 0 | 0 | 8.666 |
| Net increase / (decrease) in cash & cash equivalents (a)+(b)+(c) |
1 | 0 | 0 | 1 |
| Cash & cash equivalents at the beginning of the period |
363 | 0 | 0 | 363 |
| Cash & cash equivalents at the end of the period |
364 | 0 | 0 | 364 |
As far as it concerns the change in the items of the consolidated financial statements of the period 1/1-31/12/2008 that have been made from the finalisation of the goodwill of the new susiidaries companies that have been acquired, there is an analysis in the Note 13.
As it has already been mentioned, the Group is primarily operating in the sectors of provision of medical services, production and trade of defense technology information systems and provision of financial services and real estate, property and construction in Greece.
| Me dic al Se rvi ce s |
Inf ati orm on Te ch log no y, ad ed va nc tec hn olo d gy an ial sp ec lic ati ap p on s |
Fin cia l an Tra tio ns ac ns |
Re al Es tat e |
Eli mi tio f na n o int erc om pa ny tra tio ns ac ns |
GR OU P TO TA L |
|
|---|---|---|---|---|---|---|
| Sa les to th ird rtie pa s |
187 .54 1 |
6.6 30 |
1.6 86 |
0 | ( 45 4) |
195 .40 4 |
| Le : T ota l co st of les ss sa |
( 147 .56 4) |
( 4.5 88 ) |
( 1.2 49 ) |
0 | 25 7 |
( 153 .14 3) |
| Gr rof it ( los s) os s p |
39 .97 8 |
2.0 42 |
43 8 |
0 | ( 196 ) |
42 .26 1 |
| Ot he rat ing in r o pe co me |
3.3 34 |
30 5 |
17 1 |
0 | 0 | 3.8 09 |
| Ad mi nis tra tive ex pe nse s |
( 19 .15 8) |
( 1.2 47 ) |
( 48 1) |
0 | 0 | ( 20 .88 7) |
| Re h a nd de lop nt se arc ve me ex pe nse s |
0 | ( 179 ) |
0 | 0 | ( 0) |
( 179 ) |
| Se llin Ex g pe nse s |
( 1.7 24 ) |
( 172 ) |
( 17 ) |
0 | 0 | ( 1.9 13 ) |
| Ot he rat ing r o pe ex pe nse s |
( 77 5) |
( 70 ) |
( 150 ) |
0 | ( 49 ) |
( 1.0 43 ) |
| Op tin rof it ( los s) era g p |
21 .65 4 |
67 9 |
( 39 ) |
0 | ( 24 5) |
22 .04 9 |
| Fin t an ce cos |
( 14 .13 5) |
|||||
| Re lt o f o rdi act ivit ies su na ry |
7.9 14 |
|||||
| Inv est nt inc me om e |
( 1.5 70 ) |
|||||
| Re lts be for e t su ax es |
6.3 44 |
|||||
| Inc e t om ax es |
( 2.4 67 ) |
|||||
| Re lts af ter ta su xe s |
3.8 77 |
|||||
| Ot he r in for tio f th e I e S tat t ma n o nc om em en De cia tio nd ort iza tio n a am n |
11 .51 9 |
1.1 37 |
179 | 0 | ( ) 52 |
12 .78 3 |
| pre |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Me dic al Se rvi ce s |
Inf ati orm on Te ch log no y, ad ed va nc tec hn olo d gy an ial sp ec lic ati ap p on s |
Fin cia l an Tra tio ns ac ns |
Re al Es tat e |
Eli mi tio f na n o int erc om pa ny tio tra ns ac ns |
GR OU P TO TA L |
|
|---|---|---|---|---|---|---|
| Sa les to th ird rtie pa s |
166 .43 9 |
19 .03 2 |
1.9 56 |
0 | ( 42 7) |
187 .00 0 |
| Le : T ota l co st of les ss sa |
( 133 .64 3) |
( 15 .42 9) |
( 1.6 53 ) |
0 | 25 1 |
( 150 .47 4) |
| Gr rof it ( los s) os s p |
32 .79 6 |
3.6 03 |
30 3 |
0 | ( 17 6) |
36 .52 6 |
| Ot he rat ing in r o pe co me |
3.0 76 |
193 | 167 | 0 | 0 | 3.4 36 |
| Ad mi nis tra tive ex pe nse s |
( 17 .35 2) |
( 1.6 46 ) |
( 47 1) |
0 | 0 | ( 19 .46 8) |
| Re h a nd de lop nt se arc ve me ex pe nse s |
0 | ( 11 1) |
0 | 0 | 0 | ( 11 1) |
| Se llin Ex g pe nse s |
( 1.2 65 ) |
( 118 ) |
( 21 ) |
0 | 0 | ( 1.4 03 ) |
| Ot he rat ing r o pe ex pe nse s |
( 67 1) |
( 1.4 46 ) |
( 173 ) |
0 | ( 42 ) |
( 2.3 32 ) |
| Op tin rof it ( los s) era g p |
16 .58 4 |
47 6 |
( 196 ) |
0 | ( 21 7) |
16 .64 7 |
| Fin t an ce cos |
( 15 .94 9) |
|||||
| Re lt o f o rdi act ivit ies su na ry |
69 8 |
|||||
| Inv est nt inc me om e |
( 14 .36 3) |
|||||
| Re lts be for e t su ax es |
( 13 .66 5) |
|||||
| Inc e t om ax es |
1.8 64 |
|||||
| Re lts af ter ta su xe s |
( 11 .80 1) |
|||||
| Ot he r in for tio f th e I e S tat t ma n o nc om em en |
||||||
| De cia tio nd ort iza tio pre n a am n |
10 .72 2 |
1.8 16 |
33 7 |
0 | ( ) 43 |
12 .83 3 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
6.2.1 Other Financial Position Information (as at 30/9/2009)
| Me dic al Se rvi ce s |
Inf ati orm on Te ch log no y, ad ed va nc tec hn olo d gy an ial sp ec lic ati ap p on s |
Fin cia l an Tra tio ns ac ns |
Re al Es tat e |
Eli mi tio f na n o int erc om pa ny tra tio ns ac ns |
GR OU P TO TA L |
|
|---|---|---|---|---|---|---|
| Inv in lan nd uip est nt rty t a nt me pro pe , p eq me |
38 4 .57 |
47 | 2 | 0 | 58 5 |
39 .20 8 |
| Int ible set an g as s |
4.3 24 |
35 0 |
34 4 |
0 | ( 32 5) |
4.6 93 |
| Ta ible set ng as s |
36 4.1 01 |
19 .10 6 |
2.1 87 |
0 | 11 .87 6 |
39 7.2 70 |
| Go od wil l |
35 .96 1 |
14 .25 7 |
0 | 0 | 82 .66 6 |
132 .88 4 |
| Ho ldin d o the r in stm ts gs an ve en |
184 .58 8 |
184 .38 0 |
4.4 08 |
0 | ( 32 7.7 08 ) |
45 .66 8 |
| Inv est nt rty me pro pe |
1.2 06 |
0 | 65 1 |
28 .77 1 |
0 | 30 .62 8 |
| Ot he t it r a sse em s |
32 6.7 39 |
84 .05 1 |
14 .84 0 |
0 | ( 122 .34 9) |
30 3.2 81 |
| To tal liab iliti es |
( 61 8.0 17 ) |
( 158 .13 3) |
( 14 .38 8) |
0 | 10 1.3 53 |
( 68 9.1 84 ) |
| To tal uity eq |
29 8.9 02 |
144 .01 2 |
8.0 42 |
28 .77 1 |
( 25 4.4 86 ) |
22 5.2 40 |
| Me dic al Se rvi ce s |
Inf ati orm on Te ch log no y, ad ed va nc tec hn olo d gy an ial sp ec lic ati ap p on s |
Fin cia l an Tra tio ns ac ns |
Re al Es tat e |
f Eli mi tio na n o int erc om pa ny tra tio ns ac ns |
GR OU P TO TA L |
|
|---|---|---|---|---|---|---|
| Inv est nt in rty lan t a nd uip nt me pro pe , p eq me |
66 .64 6 |
33 8 |
22 1 |
0 | ( 14 .66 1) |
52 .54 5 |
| Int ible set an g as s |
4.4 84 |
1.0 11 |
39 3 |
0 | ( 31 1) |
5.5 77 |
| Ta ible set ng as s |
34 2.3 41 |
19 .56 5 |
2.3 14 |
0 | 5.9 65 |
37 0.1 86 |
| Go od wil l |
35 .96 1 |
14 .25 7 |
0 | 0 | 80 .24 4 |
130 .46 3 |
| Ho ldin d o the r in stm ts gs an ve en |
144 .32 4 |
186 .10 1 |
4.4 08 |
0 | ( 28 0.6 63 ) |
54 .17 0 |
| Inv est nt rty me pro pe |
1.2 06 |
0 | 65 1 |
28 .77 1 |
0 | 30 .62 8 |
| Ot he t it r a sse em s |
31 7.6 97 |
57 .88 1 |
9.4 20 |
0 | ( 106 .83 2) |
27 8.1 66 |
| To tal liab iliti es |
( 56 5.9 93 ) |
( 16 1.5 41 ) |
( 8.5 47 ) |
0 | 92 .22 8 |
( 64 3.8 53 ) |
| To tal Eq uity |
28 0.0 20 |
117 .27 4 |
8.6 39 |
28 1 .77 |
( 20 9.3 68 ) |
22 5.3 36 |
Financial income and expenses are analyzed as follows:
| GROUP | COMPANY | ||||
|---|---|---|---|---|---|
| 1/1-30/9/2009 | 1/1-30/9/2008 | 1/1-30/9/2009 | 1/1-30/9/2008 | ||
| Debit interest from banking liabilities | 14.493 | 1.374 | 2.103 | ||
| Other financial expenses | 266 | 99 | 72 | 6 | |
| Total financial expenses | 14.759 | 16.831 | 1.446 | 2.109 | |
| Credit interest and relative income | 622 | 854 | 0 | 29 | |
| Other financial income | 2 | 28 | 0 | 0 | |
| Total financial income | 624 | 882 | 0 | 29 | |
| Net financial income (expenses) | (14.135) | (15.949) | (1.446) | (2.080) |
Investment income (expenses) is analyzed as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 1/1-30/9/2009 | 1/1-30/9/2008 | 1/1-30/9/2009 | 1/1-30/9/2008 | |
| Imcome from holdings | 1.269 | 1.775 | 0 | 1.008 |
| Profit from participation in associates | 20 | 535 | 0 | 0 |
| Profits from disposal of investments | 311 | 7.506 | 0 | 552 |
| Total investment income | 1.599 | 9.817 | 0 | 1.560 |
| Expenses and losses from investments | 3.169 | 198 | 0 | 0 |
| Loss from investments valuation | 0 | 23.983 | 0 | 0 |
| Total investment expenses | 3.170 | 24.180 | 0 | 0 |
| Net income (expenses) from investments | (1.570) | (14.363) | 0 | 1.560 |
The income from holdings, € 1.269, relate to dividend income from available for sale financial assets of the Group.
Profit from participation in associates amounting to € 20, regard the participating interest of the Group proportionally on the results of associates consolidated by the equity method.
Expenses and losses from disposal of investments, amounting to € 3.169, regard the emerged result from the sale of 1.264.885 shares of the listed in the Athens Stock Exchange company IASO S.A., which is classified in the category of available for sale investment (see Note 15).
The income tax charges of the income statement are analyzed as follows:
| GROUP | COMPANY | |||||
|---|---|---|---|---|---|---|
| 1/1-30/9/2009 | 1/1-30/9/2008 | 1/1-30/9/2009 | 1/1-30/9/2008 | |||
| Income taxes | 3.758 | 7.485 | 0 | 343 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Prior years tax differences | 495 | 615 | 0 | 0 |
|---|---|---|---|---|
| Reversal of provisions of unaudited tax years | (1.254) | 0 | 0 | 0 |
| Other taxes | 287 | 325 | 0 | 63 |
| Deferred taxes | (1.800) | (11.623) | (185) | (1.357) |
| Tax provision for unaudited fiscal years | 981 | 1.334 | 90 | 186 |
| Total taxes in the Statement of comprehensive income | 2.467 | (1.864) | (95) | (764) |
| 1/1-30/9/2009 | 1/1-30/9/2008 | 1/1-30/9/2009 | 1/1-30/9/2008 | |
|---|---|---|---|---|
| Earnings / (losses) before taxes | 6.344 | (13.665) | (1.410) | 187 |
| Tax calculated by Company tax rate (2009: 25 %, 2008: 25 %) | 1.586 | (3.416) | (352) | 47 |
| Expenses non deductible according to tax legislation | 1.928 | 0 | 167 | 0 |
| Prior years tax differences | 495 | 615 | 0 | 0 |
| Reversal of provisions of unaudited tax years | (1.254) | 0 | 0 | 0 |
| Income deductible from income tax | (1.269) | (397) | 0 | (997) |
| Tax provision for unaudited fiscal years | 981 | 1.334 | 90 | 186 |
| Total taxes reported in the Statement of comprehensive income | 2.467 | (1.864) | (95) | (764) |
Basic earnings (losses) per share are calculated by dividing profits (losses) attributable to shareholders by the weighted average number of outstanding shares, including shares issued in the current year, and are analyzed as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 1/1-30/9/2009 | 1/1-30/9/2008 | 1/1-30/9/2009 | 1/1-30/9/2008 | |
| Net profit attributable to common holders of the parent | 412 | (8.188) | (1.315) | 951 |
| Weighted average number of outstanding shares | 40.511.610 | 40.511.610 | 40.511.610 | 40.511.610 |
| Less: Weighted average number of treasury shares | 1.526.349 | 2.249.715 | 127.200 | 189.706 |
| Total weighted average number of outstanding shares | 38.985.261 | 38.261.895 | 40.384.410 | 40.321.904 |
| Basic Earnings /(losses) per share (in €) | 0,0106 | (0,2140) | (0,0326) | 0,0236 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
The tangible assets of the Group are analyzed as follows:
| GROUP | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Land | Buildings and installations |
Machinery and equipment |
Transportation means |
Furniture and fixtures |
Construction in progress |
Total | ||||
| Acquisition or valuation cost | ||||||||||
| On 31/12/2008 | 117.620 | 154.957 | 124.536 | 2.115 | 28.442 | 19.690 | 447.359 | |||
| Additions in the period 1/1-30/9/2009 | 4.160 | 6.903 | 10.064 | 480 | 1.072 | 19.440 | 42.119 | |||
| Disposals in the period 1/1-30/9/2009 | 0 | (2) | (976) | (112) | (276) | (3.690) | (5.057) | |||
| Consolidation of new subsidiaries | 17 | 142 | 231 | 20 | 111 | 0 | 522 | |||
| Total on 30/9/2009 | 121.797 | 162.001 | 133.855 | 2.503 | 29.348 | 35.440 | 484.944 | |||
| Accumulated depreciation | ||||||||||
| On 31/12/2008 | 0 | 12.855 | 47.682 | 1.066 | 15.570 | 0 | 77.174 | |||
| Additions in the period 1/1-30/9/2009 | 0 | 2.748 | 7.231 | 231 | 1.346 | 0 | 11.555 | |||
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | (860) | (53) | (244) | 0 | (1.158) | |||
| Consolidation of new subsidiaries | 0 | 21 | 18 | 0 | 64 | 0 | 103 | |||
| Total on 30/9/2009 | 0 | 15.624 | 54.071 | 1.244 | 16.736 | 0 | 87.675 | |||
| Net Book value | ||||||||||
| On 31/12/2008 | 117.620 | 142.103 | 76.854 | 1.049 | 12.871 | 19.690 | 370.186 | |||
| On 30/9/2009 | 121.797 | 146.377 | 79.784 | 1.259 | 12.612 | 35.440 | 397.270 |
The depreciation of the period (including the depreciation and amortization expenses of intangible assets) charged to the cost of sales totaled to € 10.254 (2008: € 10.276), to the administrative expenses € 2.462 (2008: € 2.480), to the selling expenses € 67 (2008: € 61) and to the research and development expenses € 0 (2008: € 15).
Depreciation expenses amounting to € 4.253 (2008: € 4.432) resulting from finance lease contracts of machinery are included in the Income statement. The net book value of the leased equipment totaled € 53.188 (2008: € 49.748).
The tangible assets of the Company are analyzed as follows:
| COMPANY | |||||||
|---|---|---|---|---|---|---|---|
| Buildings and installations |
Machinery and equipment |
Transportation means |
Furniture and fixtures |
Construction in progress |
Total | ||
| Acquisition or valuation cost | |||||||
| On 31/12/2008 | 0 | 5.000 | 314 | 72 | 0 | 5.386 | |
| Additions in the period 1/1-30/9/2009 | 19 | 0 | 0 | 0 | 0 | 19 | |
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total on 30/9/2009 | 19 | 5.000 | 314 | 72 | 0 | 5.405 | |
| Accumulated depreciation | |||||||
| On 31/12/2008 | 0 | 708 | 20 | 69 | 0 | 798 | |
| Additions in the period 1/1-30/9/2009 | 0 | 290 | 50 | 0 | 0 | 340 | |
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | 0 | 0 | 0 | 0 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Total on 30/9/2009 | 0 | 999 | 69 | 69 | 0 | 1.138 | |
|---|---|---|---|---|---|---|---|
| Net Book value | |||||||
| On 31/12/2008 | 0 | 4.292 | 294 | 3 | 0 | 4.588 | |
| On 30/9/2009 | 19 | 4.001 | 244 | 3 | 0 | 4.267 | |
| The depreciation of the period (including the depreciation and amortization expenses of intangible assets) charged to the cost of sales totaled € 987 (2008: € 1.532) and to the |
administrative expenses € 0 (2008: € 15).
In the third quarter of the closing year, the Group adopted the amended version of IAS 23 prior to its implementation date, according to which the borrowing cost directly attributed to the acquisition, construction or production of an asset, which requires substantial amount of time so as to become ready for use or sale, should be included in such asset's cost. Consequently, the borrowing cost totaling to € 725, which derives from bank loans related to the construction, alteration or heavy maintenance of clinics and other relative premises, was included in the category of fixed assets under construction and did not burden the results of the Group for the closing year.
Prenotations of mortgage exist on the Groups property, amounting € 24.800 for the Company and € 93.534 for the Group for loans, letters of guarantee and security for liabilities towards the Greek government the balance of which as at 30/9/2009 was € 163.489 and € 75.569 respectively.
The intangible assets of the Group are analyzed as follows:
| GROUP | |||||
|---|---|---|---|---|---|
| Software | Concessions andRights |
Rental Rights |
Contracts | Total | |
| Acquisition or valuation cost | |||||
| On 31/12/2008 | 6.235 | 180 | 70 | 2.469 | 8.955 |
| Additions in the period 1/1-30/9/2009 | 342 | 0 | 0 | 0 | 342 |
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | 0 | 0 | 0 |
| Total on 30/9/2009 | 6.579 | 180 | 70 | 2.469 | 9.298 |
| Accumulated depreciation | |||||
| On 31/12/2008 | 1.770 | 4 | 1 | 1.603 | 3.377 |
| Additions in the period 1/1-30/9/2009 | 575 | 7 | 1 | 644 | 1.228 |
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | 0 | 0 | 0 |
| Total on 30/9/2009 | 2.345 | 11 | 2 | 2.247 | 4.605 |
| Net Book value | |||||
| On 31/12/2008 | 4.465 | 176 | 69 | 866 | 5.577 |
| On 30/9/2009 | 4.234 | 169 | 68 | 222 | 4.693 |
The intangible assets of the Company are analyzed as follows:
(Amounts are expressed in thousand Euros, unless otherwise stated)
| COMPANY | ||||||
|---|---|---|---|---|---|---|
| Software | Contracts | Total | ||||
| Acquisition or valuation cost | ||||||
| On 31/12/2008 | 41 | 2.469 | 2.511 | |||
| Additions in the period 1/1-30/9/2009 | 0 | 0 | 0 | |||
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | 0 | |||
| Total on 30/9/2009 | 41 | 2.469 | 2.511 | |||
| Accumulated depreciation | ||||||
| On 31/12/2008 | 8 | 1.603 | 1.611 | |||
| Additions in the period 1/1-30/9/2009 | 2 | 644 | 647 | |||
| Disposals in the period 1/1-30/9/2009 | 0 | 0 | 0 | |||
| Total on 30/9/2009 | 9 | 2.247 | 2.258 | |||
| Net Book value | ||||||
| On 31/12/2008 | 33 | 866 | 900 | |||
| On 30/9/2009 | 31 | 222 | 253 |
The movement of goodwill for the closing period is analyzed as follows:
| SEGMENT | Balance on 31/12/2008 |
Additions/ (decreases)) |
Impairment | Balance on 30/9/2009 |
||
|---|---|---|---|---|---|---|
| HEALTH | 95.147 | 2.422 | 0 | 97.569 | ||
| FINANCIAL SERVICES | 0 | 0 | 0 | 0 | ||
| ADVANCED TECHNOLOGY APPLICATIONS |
& | SPECIAL | 35.316 | 0 | 0 | 35.316 |
| 130.463 | 2.422 | 0 | 132.884 |
Within the closing period, the Group acquired control over two new (3) subsidiary companies: (1) D.S. SIOVAS – RADIODIAGNOSTIC CENTER GREVENA, which operates a diagnostic center in the city of Grevena, (2) ASKLEPIO INFIRMARY LARISA S.A., which operates a diagnostic center of open nursing in the city of Larisa and (3) of ALFA NEFRODYNAMIKI S.A. which provides specialized dialysis services in the city of Serres.
The resulting goodwill from these acquisitions was determined based on the book values of the balance sheet of the acquired companies and is provisional. The determination of the fair value of the assets, liabilities and contingent liabilities of each of the acquired company, as well as the allocation of the take over value was based on the provisions of the IFRS 3 "Business Combinations" and the resulting final determination of the goodwill will be accomplished in a posterior period, because the Group has followed the provisions of that Standard regarding the finalization of the above mentioned figures within twelve months from the acquisition date of the Company.
The book acquisition values, the total price of the acquisition and the resulting provisional goodwill for the Group at 1/2/2009, acquisition date of the company D.S. SIOVAS – RADIODIAGNOSTIC CENTER GREVENA, are as follows:
| Book values at the date of first consolidation |
|
|---|---|
| ASSETS | |
| Tangible assets | 49 |
| Cash and cash equivalents | 3 |
| Total assets | 52 |
| LIABILITIES | |
| Suppliers and other liabilities | 3 |
| Total Liabilities | 3 |
| Net value of assets | 49 |
| Total acquisition cost | 359 |
| Less: Net value of acquired assets (30,2 %) | (15) |
| Less: Third parties percentage on the initial investment (indirect participation) | (138) |
| Resulting provisional goodwill | 206 |
The book acquisition values, the total price of the acquisition and the resulting provisional goodwill for the Group at 1/3/2009, acquisition date of the company ASKLEPIO INFIRMARY LARISA S.A., are as follows:
| Book values at the date of first |
|
|---|---|
| consolidation | |
| ASSETS | |
| Tangible assets | 327 |
| Intangible assets | 2 |
| Long-term assets | 8 |
| Trade and other receivables | 1.599 |
| Cash and cash equivalents | 72 |
| Total assets | 2.008 |
| LIABILITIES | |
| Long-term bank liabilities | 220 |
| Deferred tax liabilities | 5 |
| Short-term bank liabilities | 219 |
| Suppliers and other liabilities | 635 |
| Short-term tax liabilities | 413 |
| Total liabilities | 1.492 |
| Net value of assets | 515 |
| Total acquisition cost | 2.226 |
| Less: Net value of acquired assets (37,5 %) | (192) |
| Less: Third parties percentage on the initial investment (indirect participation) | (841) |
| Resulting provisional goodwill | 1.193 |
The book acquisition values, the total price of the acquisition and the resulting provisional goodwill for the Group at 22/8/2009, acquisition date of the company ALFA NEFRODYNAMIKI S.A., are as follows:
| Book values at the date of first consolidation |
|
|---|---|
| ASSETS | |
| Tangible assets | 43 |
| Inventory | 20 |
| Trade and other receivables | 480 |
| Cash and cash equivalents | 40 |
| Total Assets | 583 |
| LIABILITIES Suppliers and other liabilities Short-term tax liabilities |
522 1 |
| Total Liabilities | 523 |
| Net value of assets | 60 |
| Total acquisition cost | 2.000 |
| Less: Net value of acquired assets (29,2 %) | (18) |
| Less: Proportion of third in the initial investment (indirect participation) | (756) |
| Resulting provisional goodwill | 1.227 |
The respective amounts of goodwill that resulted from the acquisitions of the subsidiary companies IPPOKRATIS MAGNETIC TOMOGRAPHY S.A. DIAGNOSTIC CENTER OF LARISSA SA, NEUROLOGICAL PSYCHIATRY PISSALIDI A. - A. KARIPIS SA, ALEXANDREIO PRIVATE DIAGNOSTIC LABORATORY MEDICINE SA, PRIVATE DIAGNOSTIC LABORATORY WEST THESSALONIKI I.A.E. and VOGIATZIS PRIVATE DIAGNOSTIC LABORATORY I.A.E. were determined based on the book values of the balance sheet of the acquired companies and are finalized.
The book values and fair acquisition values, total acquisition price and resulting finalized goodwill for the Group on 1/2/2008, i.e. acquisition date of IPPOKRATIS MAGNETIC TOMOGRAPHY S.A., are as follows:
| Fair values at the date of goodwill finalisation |
Book values at the date of first consolidation |
|
|---|---|---|
| ASSETS | ||
| Tangible assets | 182 | 13 |
| Intangible assets | 1 | 0 |
| Long-term assets | 3 | 3 |
| Deferred tax assets | 33 | 0 |
| Inventories | 10 | 10 |
| Trade and other receivables | 567 | 840 |
| Cash and cash equivalents | 136 | 136 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| TotalAssets | 931 | 1.002 |
|---|---|---|
| LIABILITIES | ||
| Provisions for contingent risks and expenses | 2 | 0 |
| Suppliers and other liabilities | 78 | 78 |
| Short-term tax liabilities | 61 | 61 |
| Total liabilities | 142 | 140 |
| Net value of assets | 790 | 862 |
| Total acquisition cost | 510 | |
| Less: Net value of acquired assets (27,5 %) | (217) | |
| Less: Third parties percentage on the initial investment (indirect participation) | (345) | |
| Resulting finalized (negative) goodwill | (52) |
The book values and fair acquisition values, total acquisition price and resulting finalized goodwill for the Group on 15/9/2008, i.e. acquisition date of DIAGNOSTIC CENTER OF LARISSA S.A., are as follows:
| Fair values at the date of goodwill finalisation |
Book values at the date of first consolidation |
|
|---|---|---|
| ASSETS | ||
| Tangible assets | 39 | 29 |
| Intangible assets | 127 | 0 |
| Long-term receivables | 2 | 2 |
| Deferred tax assets | 16 | 26 |
| Trade and other receivables | 171 | 376 |
| Cash and cash equivalents | 16 | 62 |
| Total Assets | 373 | 496 |
| LIABILITIES | ||
| 11 | 0 | |
| Short-term bank liabilities | 70 | 29 |
| Suppliers & other liabilities | 95 | 144 |
| Short-term tax liabilities | 23 | 10 |
| Total Liabilities | 199 | 183 |
| Net value of assets | 174 | 312 |
| Total acquisition cost | 450 | |
| Less: Net value of assets acquired (25,8%) | (45) | |
| Less: Third parties percentage on the initial investment (indirect participation) |
(256) | |
| Resulting finalized goodwill | 149 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
The book values and fair acquisition values, total acquisition price and resulting finalized goodwill for the Group on 22/8/2008, i.e. acquisition date of NEUROLOGICAL PSYCHIATRY PISSALIDI A. - A. KARIPIS S.A., are as follows:
| Fair values at the date of goodwill finalisation |
Book values at the date of first consolidation |
|
|---|---|---|
| ASSETS | ||
| Tangible assets | 17 | 25 |
| Intangible assets | 1 | 0 |
| Deferred tax assets | 216 | 0 |
| Trade and other receivables | 328 | 1.121 |
| Cash and cash equivalents | 67 | 225 |
| Total Assets | 629 | 1.370 |
| LIABILITIES | ||
| Provision for staff retirement indemnities | 63 | 0 |
| Other proviisions | 5 | 0 |
| Short-term bank liabilities | 119 | 0 |
| Suppliers & other liabilities | 174 | 174 |
| Short-term tax liabilities | 0 | 119 |
| Total Liabilities | 361 | 293 |
| Net value of assets | 268 | 1.077 |
| Total acquisition cost | 3.150 | |
| Less: Net value of assets acquired (30,8%) | (83) | |
| Less: Third parties percentage on the initial investment (indirect participation) |
(1.212) | |
| Resulting finalized goodwill | 1.855 |
The book values and fair acquisition values, total acquisition price and resulting finalized goodwill for the Group on 30/9/2008, i.e. acquisition date of ALEXANDREIO PRIVATE DIAGNOSTIC LABORATORY MEDICINE S.A., are as follows:
| Fair values at the date of goodwill finalisation |
Book values at the date of first consolidation |
|
|---|---|---|
| ASSETS | ||
| Tangible assets | 1.571 | 455 |
| Intangible assets | 2 | 2 |
| Long-term receivables | 2 | 2 |
| Deferred tax assets | 29 | 2 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Inventories | 2 | 0 |
|---|---|---|
| Trade and other receivables | 1 | 1 |
| Cash and cash equivalents | 84 | 154 |
| Total Assets | 1.691 | 616 |
| LIABILITIES | ||
| Long term bank loans | 0 | 0 |
| Provision for staff retirement indemnities | 47 | 0 |
| Long term finance lease liabilities | 907 | 0 |
| Short term finance lease liabilities | 202 | 0 |
| Short-term bank liabilities | 350 | 350 |
| Suppliers & other liabilities | 322 | 253 |
| Short-term tax liabilities | 0 | 0 |
| Total Liabilities | 1.829 | 603 |
| Net value of assets | (138) | 13 |
| Total acquisition cost | 103 | |
| Less: Net value of acquired assets (30,1%) | 42 | |
| Less: Third parties percentage on the initial investment (indirect participation) |
(40) | |
| Resulting finalized goodwill | 105 |
The book values and fair acquisition values, total acquisition price and resulting finalized goodwill for the Group on 15/9/2008, i.e. acquisition date of PRIVATE DIAGNOSTIC LABORATORY WEST THESSALONIKI S.A., are as follows:
| Fair values at the date of goodwill finalisation |
Book values at the date of first consolidation |
|
|---|---|---|
| ASSETS | ||
| Tangible assets | 1.164 | 84 |
| Intangible assets | 102 | 2 |
| Long-term receivables | 2 | 2 |
| Deferred tax assets | 16 | 3 |
| Inventories | 5 | 0 |
| Trade and other receivables | 203 | 297 |
| Cash and cash equivalents | 106 | 121 |
| Total Assets | 1.598 | 510 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Long term bank loans | 0 | |
|---|---|---|
| Provision for staff retirement indemnities | 1 | 0 |
| Long term finance lease liabilities | 877 | 0 |
| Short term finance lease liabilities | 196 | 0 |
| Short-term bank liabilities | 0 | 0 |
| Suppliers & other liabilities | 249 | 185 |
| Short-term tax liabilities | 1 | 0 |
| Total Liabilities | 1.324 | 185 |
| Net value of assets | 275 | 325 |
| Total acquisition cost | 198 | |
| Less: Net value of acquired assets (25,8%) | (71) | |
| Less: Third parties percentage on the initial investment (indirect participation) |
(76) | |
The book values and fair acquisition values, total acquisition price and resulting finalized goodwill for the Group on 15/9/2008, i.e. acquisition date of VOGIATZIS PRIVATE DIAGNOSTIC LAB S.A., are as follows:
| Fair values at the date of goodwill finalisation |
Book values at the date of first consolidation |
|
|---|---|---|
| ASSETS | ||
| Tangible assets | 299 | 137 |
| Intangible assets | 0 | |
| Long-term receivables | 1 | 1 |
| Deferred tax assets | 0 | 1 |
| Inventories | 9 | 9 |
| Trade and other receivables | 160 | 246 |
| Cash and cash equivalents | 33 | 33 |
| Total Assets | 502 | 427 |
| LIABILITIES | ||
| Long term bank loans | 57 | 57 |
| Deferred tax liabilities | -8 | |
| Long term finance lease liabilities | 68 | |
| Short term finance lease liabilities | 28 | |
| Short-term bank liabilities | ||
| Suppliers & other liabilities | 257 | 257 |
| Short-term tax liabilities | 9 | 9 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Total Liabilities | 412 | 323 |
|---|---|---|
| Net value of assets | 91 | 105 |
| Total acquisition cost | 454 | |
| Less: Net value of acquired assets (29,5%) | (27) | |
| Less: Third parties percentage on the initial investment (indirect participation) |
(175) | |
| Resulting finalized goodwill | 252 |
It is noted that the fair value of the assets, liabilities and contingent liabilities as well as the resulting goodwill of the aforementioned acquired companies were finalized within the closing period, the comparative statement of the financial position, the statement of the comprehensive income and the Group's cash flow statements on 31st December 2008 were reformed in order to include the finalized figures which resulted from the finalization of the purchase price allocation process.
The changes of the items in the consolidated financial statement, in the consolidated statement of comprehensive income and in the consolidated cash flow statement for the period that ended on 31/12/2008 are as follows:
| STATEMENT OF FINANCIAL POSITION | Balance on 31/12/2008 as previously published |
Correction after the finalisation of goodwill |
Reformed balance on 31/12/2008 |
|---|---|---|---|
| ASSETS | |||
| Non-Current Assets: | |||
| Tangible assets | 368.993 | 1.193 | 370.186 |
| Intangible assets | 5.450 | 127 | 5.577 |
| Goodwill | 130.108 | 355 | 130.463 |
| Investments in associates | 6.423 | 0 | 6.423 |
| Available for sale investments | 47.747 | 0 | 47.747 |
| Investment property | 30.628 | 0 | 30.628 |
| Non current receivables | 16.614 | 0 | 16.614 |
| Deferred income taxes | 1.680 | 246 | 1.925 |
| Total Non-Current Assets: | 607.642 | 1.920 | 609.563 |
| Current Assets: | |||
| Inventories | 27.064 | 0 | 27.064 |
| Customers and other receivables | 195.893 | (1.726) | 194.168 |
| Financial assets at fair value through income statement | 9 | 0 | 9 |
| Cash and cash equivalents | 38.660 | (274) | 38.386 |
| Total current assets | 261.627 | (2.000) | 259.627 |
| TOTAL ASSETS | 869.269 | (80) | 869.189 |
| EQUITY AND LIABILITIES Equity |
|||
| Share capital | 24.712 | 0 | 24.712 |
| Premium on capital stock | 33.373 | 0 | 33.373 |
| Reserves | 4.042 | 5 | 4.047 |
| Accumulated profits (deficit) | 59.440 | (84) | 59.356 |
| Treasury shares | (12.866) | 0 | (12.866) |
|---|---|---|---|
| Total Equity attributed parent company | 108.701 | (79) | 108.622 |
| Minority interests | 117.804 | (1.090) | 116.714 |
| Total Equity | 226.505 | (1.169) | 225.336 |
| LIABILITIES | |||
| Non-Current Liabilities | |||
| Loans | 300.723 | 774 | 301.497 |
| Provision for staff retirement indemnities | 6.396 | 72 | 6.468 |
| Other provisions | 4.247 | 0 | 4.247 |
| Deferred income taxes | 27.875 | (36) | 27.839 |
| Grants for investments in fixed assets | 2.794 | 0 | 2.794 |
| Other long term obligations | 1.163 | 0 | 1.163 |
| Non-Current Liabilities | 343.198 | 811 | 344.008 |
| Current Liabilities | |||
| Suppliers and other current liabilities | 176.692 | 87 | 176.779 |
| Short-term loans | 108.508 | 192 | 108.700 |
| Income taxes payable | 14.366 | 0 | 14.366 |
| Total current liabilities | 299.566 | 279 | 299.845 |
| TOTAL LIABILITIES | 642.764 | 1.089 | 643.853 |
| TOTAL EQUITY AND LIABILITIES | 869.269 | (80) | 869.189 |
| Balance on | Correction after | Reformed | |
| 31/12/2008 as previously |
the finalisation | balance on | |
| published | of goodwill | 31/12/2008 | |
| STATEMENT OF COMPREHENSIVE INCOME | |||
| Sales | 251.708 | (361) | 251.347 |
| Minus: Cost of goods sold | (200.834) | 29 | (200.805) |
| Gross profit | 50.874 | (332) | 50.542 |
| Other operating income | 5.375 | 19 | 5.393 |
| 56.248 | (313) | 55.936 | |
| Administrative expenses | (27.411) | (61) | (27.472) |
| Research and development expenses | (402) | 0 | (402) |
| Distribution expenses Other operating expenses |
(3.212) (3.388) |
5 1 |
(3.207) (3.388) |
| Operating results | 21.835 | (368) | 21.466 |
| Financing cost | (22.499) | (6) | (22.505) |
| Results of ordinary activities | (665) | (374) | (1.039) |
| Income from Investments | (14.756) | 19 | (14.736) |
| Results before income taxes | (15.420) | (354) | (15.775) |
| Income taxes | 3.044 | 5 | 3.049 |
| Results after income taxes | (12.377) | (349) | (12.726) |
| Distributed to: | |||
| - Owners of the parent | (9.632) | (83) | (9.714) |
| - Minority interests | (2.745) | (267) | (3.012) |
| Total comprehensive income after taxes: | |||
| Revaluation of investments in fair values | (14.556) | 0 | (14.556) |
| Revaluation of assets in fair values Tax income on other operating income |
0 6.559 |
0 0 |
0 6.559 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Total tax income of the other comprehensive income Total tax income after taxes |
(7.998) (20.375) |
0 (349) |
(7.998) (20.724) |
|---|---|---|---|
| Distributed to: | |||
| - Owners of the parent | (14.629) | (83) | (14.712) |
| - Minority interests | (5.746) | (267) | (6.012) |
| Earnings per share (€ per share) | |||
| Basic | (0,2518) | (0,2540) |
Investments of the Company in subsidiary companies and the relative changes for the current period are analyzed as follows:
| COMPANY | Balance 31/12/2008 |
Additions | Disposals | Merger | Balance 30/9/2009 |
|---|---|---|---|---|---|
| EUROMEDICA S.A. | 72.370 | 0 | 0 | 0 | 72.370 |
| SONAK S.A. | 29.219 | 0 | 0 | 0 | 29.219 |
| AXON SECURITIES S.A. | 4.516 | 0 | 0 | 0 | 4.516 |
| EGKEFALOS PELOPONISOU S.A | 0,3 | 0 | 0 | 0 | 0,3 |
| PANCRETE HOLDING MUTUAL FUND | 104 | 0 | 0 | 0 | 104 |
| EUROMEDICA ALBANIA HOLDINGS S.A. | 16 | 0 | 0 | 0 | 16 |
| ΑΧΟΝ FINANCE S.A. | 180 | 0 | 0 | 0 | 180 |
| EUROMEDICA REAL ESTATE S.A. | 0 | 60 | 0 | 0 | 60 |
| EUROMEDICA GULF HOLDINGS S.A. | 0 | 2 | 0 | 0 | 2 |
| 106.405 | 61 | 0 | 0 | 106.466 |
Regarding the acquisition cost of the recently acquired companies EUROMEDICA S.A. REAL ESTATE and EUROMEDICA GULF HOLDINGS S.A. information is offered in Note 3.
Available for sale financial assets represent participating interests in the following companies:
| GROUP | ||||
|---|---|---|---|---|
| COMPANIES | 30/9/2009 | 31/12/2008 | ||
| Book value | Participation percentage |
Book value | Participation percentage |
|
| IASO S.A. | 22.253 | 6,8% | 29.892 | 7,8% |
| EUROMEDICA HEART S.A. | 15 | 0,0% | 15 | 0,6% |
| ST. LOUKAS NURSERY S.A. | 2.101 | 3,8% | 2.101 | 3,7% |
| GENIKI KLINIKI GAVRILAKI S.A. | 2.053 | 9,2% | 1.917 | 8,2% |
| ΑΧΟΝ EMPORIKI S.A. | 2.043 | 0,0% | 2.043 | 0,0% |
| SOUROTI S.A. | 4.005 | 5,2% | 5.725 | 7,4% |
| FILOKTITIS S.A. | 3.112 | 3,7% | 3.112 | 3,2% |
| Total | 38.584 | 47.747 | ||
|---|---|---|---|---|
| PANCRETA RADIOTELEVISION | 9 | - | 9 | - |
| COOPERATIVE BANK OF KATERINI | 1 | - | 1 | - |
| PAE NIKI VOLOU | 2 | - | 0 | - |
| COOPERATIVE BANK OF KORINTHIA | 3 | - | 3 | - |
| AXON TANEO FUND | 2.850 | 50,0% | 2.791 | 50,0% |
| ASKLEPIEIO CRETE S.A | 139 | 0,3% | 139 | 0,3% |
Available for sale financial assets for which an active market where their shares are traded does not exist, are represented at acquisition cost, impaired to the extent the relative conditions apply, and are recognized in the statement of comprehensive income of the period in which the impairment loss occurs.
In the current period available for sale investments of the Group changed as follows:
The subsidiary company of the Group EUROMEDICA S.A. proceeded in selling 1.264.885 shares of the company IASO S.A. from which a loss of € € 3.169 emerged, which in turn was disclosed in the results of the closing period. As of 30/9/2009, the Group owned 5.467.456 (2008: 6.732.341) shares of the company IASO S.A. The valuation of the shares mentioned above resulted in a profit after tax of € 622 (€ 387 for the Group) that has been disclosed, through the statement of comprehensive income, in the equity of the Group and more particularly in the account "Reserve from revaluation of investments in fair value"
The subsidiary company of the Group EUROMEDICA S.A. during the current period signed an agreement for the acquisition of an extra 0,6% of GENIKI KLINIKI GAVRILAKI S.A. share for a total amount of € 135.
The total accounts receivable of the Group and the Company are analyzed as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 | |
| Trade debtors | 138.004 | 120.988 | 1.274 | 1.789 |
| Notes receivable | 6.448 | 4.447 | 0 | 0 |
| Notes delayed | 11 | 11 | 0 | 0 |
| Cheques receivable | 961 | 1.345 | 0 | 0 |
| Cheques delayed | 134 | 168 | 0 | 0 |
| Short-term receivables from associates | 0 | 39 | 39 | 17 |
| Short-term receivables from other participations | 7.536 | 6.848 | 0 | 0 |
| Advances and credits management accounts | 906 | 811 | 0 | 0 |
| Long-term receivables payed in next period | 7.269 | 2.810 | 0 | 0 |
| Doubtful accounts receivable | 2.088 | 2.410 | 0 | 0 |
| Other debtors | 28.551 | 23.056 | 71 | 70 |
| Advances and prepayments accounts | 1.014 | 1.999 | 0 | 0 |
| Deferred charges | 1.416 | 834 | 10 | 9 |
| Accrued income | 41.174 | 40.084 | 0 | 0 |
| Other prepayments and accrued income | 1.639 | 407 | 0 | 0 |
| 237.151 | 206.257 | 1.393 | 1.885 | |
| Less: Provisions | (12.516) | (12.089) | 0 | 0 |
| Total | 224.635 | 194.168 | 1.393 | 1.885 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
The majority of the trade receivables of the Group concern receivables from social security institutions and insurance companies regarding medical services rendering as well as receivables from fulfillment of IT and advanced technology projects in which, in most cases, the counterparty is the Greek State. The greatest credit risk of trades receivable amounts up to their book value.
At 30/9/2009, the trade and other receivables of the Group and the Company amounting to 12.516 (2008: € 12.089) and € 0 (2008: € 0) respectively were impaired. Those receivables are receivables from private clients and insurance companies and concern receivables with aging balance more than a year.
The movement of the provisions of impaired receivables is as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 | |
| Opening balance | 12.089 | 10.677 | 0 | 396 |
| Provisions of doubtful receivables | 427 | 1.240 | 0 | 0 |
| Deletion of receivables in current period as irrecoverable | 0 | (1.558) | 0 | 0 |
| Reverse of unused provisions | 0 | (396) | 0 | (396) |
| Bad debt provisions of new subsidiaries | 0 | 2.126 | 0 | 0 |
| Closing Balance | 12.516 | 12.089 | 0 | 0 |
Provisions of impairment of trade receivables are incorporated in the account "Selling expenses".
The Group and the Company at 30/9/2009 held 2.302.173 and 191.854 treasury shares (shares of the parent company), which were acquired for a total amount of € 12.866 and € 917 respectively. Those amounts appear in the Consolidated Statement of Financial Position as a deduction of equity.
The loans of the Group have been issued by Greek Banks and are denominated in Euro. The amounts payable within a year from the date of the Statement of Financial Position are characterized as short-term liabilities, while amounts payable at a later period are characterized as long-term liabilities.
On 5/3/2009, the subsidiary company EUROMEDICA S.A. proceeded in issuing a bond loan amounting to € 30.000 having as payment proxy and bondholders representative the NATIONAL BANK OF GREECE. The loan rate was set at Euribor plus a margin and the expiry date of the loan at 5/3/2017. It is noted that out of the total amount of the convertible bond € 30.000, part of it, an amount of € 15.000 was paid in advance during the fourth semester of the previous year. In addition, the subsidiary company of the Group EUROMEDICA S.A. made an early repayment of an amount of € 10.000 in March of the current year, which is part of loan capital obtained from ΕΜPΟRΙΚI BANK, the balance of
which at 30/9/2009 amounted to € 80.000.
The subsidiary company of the Group, EUROMEDICA AROGI AHAIAS S.A. on 13/3/2009 proceeded in issuing a bond loan amounting to € 5.000 having as payment proxy and bondholders representative the EFG EUROBANK ERGASIAS S.A.. The loan rate was set at Euribor plus a margin and the expiry date of the loan at 13/3/2019.
The Group sets up provisions for accrued loan interest which is recognized in the statement of comprehensive income of the respective period.
The finance lease liabilities concern the leasing of machinery and other equipment, and are analyzed as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 | |
| Within 1 year | 9.567 | 8.792 | 5.154 | 5.243 |
| Between two and five years | 25.453 | 25.465 | 14.927 | 14.703 |
| Over five years | 1.908 | 1.748 | 1.025 | 597 |
| 36.928 | 36.005 | 21.106 | 20.542 | |
| Future financial cost charges in finance lease | (4.231) | (4.605) | (2.913) | (2.655) |
| 32.697 | 31.401 | 18.193 | 17.887 |
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 | |
| Within 1 year | 8.008 | 6.965 | 4.215 | 4.299 |
| Between two and five years | 23.399 | 22.917 | 13.381 | 13.009 |
| Over five years | 1.290 | 1.519 | 596 | 580 |
| 32.697 | 31.401 | 18.193 | 17.887 |
There is a withholding of ownership on the leased assets, which remains in effect until the end of the lease period and the full repayment of the lease payments due.
For reassurance of the loan liabilities mentioned above there has been mortgage prenotations on the tangible assets of the Group of a total amount € 93.534 and a pledge of 22.596.731 stocks of the subsidiary company EUROMEDICA S.A..
At the end of the closing period the Group did not maintain the minimum proportion of certain financial ratios as provided by loan contracts with the following banks:
(Amounts are expressed in thousand Euros, unless otherwise stated)
| BANK | LOAN AMOUNT |
|---|---|
| EMPORIKI BANK | 80.000 |
| PIRAEUS BANK | 60.000 |
| PIRAEUS BANK | 25.000 |
| NATIONAL BANK OF GREECE |
30.000 |
| CYPRUS BANK | 10.000 |
The Group is in renegotiation process regarding the terms of the bank loan, which is expected to be completed by the end of the current year and possibly lead to an increase of financial expenses. Regarding the first bank loan the Group made an early repayment for a total amount of € 10.000 in December 2008 and for an additional amount of € 10.000 in March 2009.
The obligation of both the Group and the Company towards employees working in Greece for the future provision of benefits in relation to their past service is accounted for and represented on the basis of the expected payable accrued benefit of every employee at the date of the Statement of Financial Position, discounted at its present value, in relation to its foreseen time of payment. The accrued benefits of every period are charged to the Statement of Comprehensive Income with a respective increase of the pension liability. The payment of benefits towards retiring employees proportionally decreases the pension liability.
The number of employees of the Group and the Company and their compensation expenses are as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 30/9/2008 | 30/9/2009 | 30/9/2008 | |
| Number of employees: | ||||
| Permanent | 2.671 | 2.503 | 8 | 15 |
| Wage-earners | 5 | 0 | 0 | 0 |
| Total | 2.676 | 2.503 | 8 | 15 |
| Employee cost analysis: | ||||
| Salary and wage expenses | 53.565 | 47.991 | 293 | 401 |
| Provision for staff retirement indemnities | 1.209 | 812 | 48 | 44 |
| Total | 54.774 | 48.803 | 341 | 445 |
Other provisions relate to formulated provisions for the coverage of future costs and expenses that may arise upon termination of social security liabilities and additional taxes that may arise from the tax audit of unaudited fiscal years by the tax authorities. More specifically:
(Amounts are expressed in thousand Euros, unless otherwise stated)
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 | |
| Provisions for social security liabilities termination | 109 | 109 | 0 | 0 |
| Provisions for subsidiary company liquidation completion | 25 | 25 | 0 | 0 |
| Provisions for additional taxes from unaudited fiscal years | 3.139 | 4.113 | 393 | 860 |
| Balance | 3.273 | 4.247 | 393 | 860 |
During the current period the regular tax audit for the unaudited fiscal years of certain companies of the Group has been finalised. A relative analysis is disclosed in Note 22.4.The total of all additional taxes and penalties incurred amounted to € 1.281, which was covered entirely from formed provisions for unaudited fiscal years amounting to € 1.811. The remaining amount of the formed provision of an amount of € 530 has been classified to the statement of comprehensive income.
The total obligations of both Group and Company towards suppliers and others third parties are analyzed as follows:
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 30/9/2009 | 31/12/2008 | 30/9/2009 | 31/12/2008 | |
| Suppliers | 75.195 | 71.851 | 1.453 | 2.435 |
| Notes payable | 12.253 | 7.169 | 0 | 0 |
| Cheques payable | 24.790 | 11.775 | 3 | 3 |
| Customers' advances | 68.212 | 67.073 | 37 | 767 |
| Social security contributions | 4.811 | 6.619 | 7 | 25 |
| Liabilities owed to associated companies | 0 | 0 2 |
2 | |
| Liabilities owed to affiliated companies | 934 | 125 | 0 | 0 |
| Dividends payable | 270 | 299 | 270 | 299 |
| Sundry creditors | 13.002 | 9.233 | 808 | 1.252 |
| Accrued and deferred income | 158 | 38 0 |
0 | |
| Accrued expenses | 4.727 | 2.338 | 218 | 42 |
| Other accruals | 192 | 259 | 0 | 0 |
| Total | 204.545 | 176.779 | 2.798 | 4.826 |
The Company considers as related parties the members of the Board of Directors (including their related parties), as well as the shareholders holding a percentage greater than 5% of its share capital. The Group's and Company's transactions and balances, in the period 1/1-30/9/2009 and at 30th September 2009, respectively, were the following:
| GR OU P |
||||||||
|---|---|---|---|---|---|---|---|---|
| Re lat ed rtie pa s |
Inc om e fro m rel ate d rtie pa s |
De rip tio sc n of inc om e |
Ex pe nc es fro m rel ate d rtie pa s |
De rip tio sc n of ex pe ns es |
Re iva ble ce s fro rel d ate m rtie pa s |
De rip tio sc n of eiv ab les rec |
Lia bil itie s rel d to ate rtie pa s |
De rip tio sc n of lia bil itie s |
| Τα π |
ά ε ίνα οσ ι ε εφ κπ |
έν ιλι άδ ρα σμ α σ ε χ |
ώ ες ευρ |
|||||
| EU RO GE NE TIC A S A |
29 | ( 8) |
167 | ( 2) |
32 | ( 8) |
83 | ( 2) |
| RO N S ME DIT A |
0 | 34 0 |
( 19 ) |
0 | 37 5 |
( 19 ) |
||
| ME DIT RE ND SA |
0 | 31 | ( 1) |
0 | 31 | ( 1) |
||
| EU RO ME DIC A c tic PR IVA TE PO LY IAT RIO I.A .E. os me |
10 | ( 8) |
0 | 25 | ( 4) |
0 | ||
| CE NT RA L M ED ICA L S ER VIC ES SA ( HE AL TH La riss a) |
20 0 |
( 4) |
0 | |||||
| 0 | 0 | 13 .46 5 |
( ) 12 |
0 | ||||
| ON S. CO RC AX A. ME IAL |
0 | 0 | 3.0 05 |
( ) 13 |
0 | |||
| 0 | 0 | 33 | ( 3) |
0 | ||||
| 0 | 0 | 20 0 |
( 4) |
0 | ||||
| ON OP S. AX D EV EL ME NT A. |
0 | 1.8 05 |
( 9) |
8.6 77 |
( 9) |
97 9 |
( 9) |
|
| ON ION S. AX IN TE RN AT AL A. |
0 | 0 | 0 | 0 | ( ) 16 |
|||
| BY RO N I NC |
0 | 0 | 1.1 79 |
( 15 ) |
0 | ( 14 ) |
||
| HO JE NT RP E I NV LT D |
0 | 0 | 0 | 0 | ( 3) |
|||
| PE KR IST IN V L TD |
0 | 0 | 0 | 0 | ( 3) |
|||
| LU CIN DA H OL DIN GS LT D |
0 | 0 | 0 | 0 | ( 3) |
|||
| ST AR EN GI NE ER ING SA |
0 | 0 | 0 | 0 | ( 17 ) |
|||
| GE NE RA L C LIN IC S.A . G rila ki av |
23 | ( 2) |
0 | 26 5 |
( 2) |
31 0 |
( 2) |
|
| EU RO ME DIC A H EA RT S. A. |
2 | ( 18 ) |
0 | 31 | ( 11 ) |
1.0 99 |
( 11 ) |
|
| EV RO TH ER AP EIA S. A. |
30 0 |
( 5) |
0 | 20 2 |
( 5) |
0 | ||
| PR OF IT PU BL ISH ING S. A. |
1 | ( 8) |
85 | ( 10 ) |
0 | 39 | ( 10 ) |
|
| 36 5 |
2.4 27 |
27 .31 5 |
2.9 17 |
| Co | mp | an y |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Re lat ed rtie pa s |
Inc om e fro m rel ate d rtie pa s |
De rip tio sc n of inc om e |
Ex pe nc es fro m rel ate d rtie pa s |
De rip tio sc n of ex pe ns es |
Re iva ble ce s fro rel ate d m rtie pa s |
De rip tio sc n of eiv ab les rec |
Lia bil itie s to rel ate d rtie pa s |
De rip tio sc n of lia bil itie s |
|
| Τα π |
ά ε ίνα οσ ι ε κπ εφ |
ρα σμ |
έν ιλι άδ α σ ε χ |
ώ ες ευρ |
|||||
| EU RO GE NE TIC A S A |
29 1 |
0 | 0 | 50 7 |
( 18 ) |
||||
| SO NA K S A |
0 | 0 | 11 | ( 11 ) |
0 | ||||
| AX ON S. A. CO ME RC IAL |
0 | 4 | ( 18 ) |
19 | ( 4) |
0 | |||
| AX ON SE CU RIT IES S. A. |
0 | 3 | ( 18 ) |
0 | 0 | ||||
| AX ON D EV EL OP ME NT S. A. |
0 | 0 | 0 | 0 | |||||
| KE RD OS PU BL ISH ING |
0 | 6 | ( 10 ) |
0 | 2 | ( 10 ) |
|||
| AX ON IN TE RN AT ION AL S. A. |
0 | 0 | 0 | 98 | ( 6) |
||||
| SA GIT A I NT ER NA TIO NA L |
0 | 0 | 0 | 1 | ( 6) |
||||
| EG EF AL OS PE LO PO NIS OU S. A. |
0 | 0 | 8 | ( 11 ) |
0 | ||||
| 29 1 |
13 | 39 | 60 7 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
(1) Trade transactions in medical consumables, sanitary material and medical services
All manner of BoD Members and Management Executives fees of both Group and Company during the closing period amounted to € 333 and € 111 respectively. As at 30/9/2009 no claims of the Group and the Company exist from and to BoD Members and Management Executives.
On 30/9/2008 there are pending lawsuits, extrajudicial calls and in general future claims against companies of the Group and the Company totaling € 47.032 (2008: € 48.280) and € 0 (2008:0) respectively. The outcome of the above cases could not be predicted according to the available information to Groups' management and as a result no relative provision to the financial statements has been made. The Group's legal department estimates that all lawsuits are expected to be settled without any material adverse effect on the Group's financial position and its operations.
Moreover, tax liabilities concerning value added tax totaling to € 11.461 have been imputed regarding the subsidiary company of the Group SONAK S.A. by the Athens Inter-regional Auditing Center. Appeals have been filed against the relevant acts of the value added tax assessment, their hearing pending before the Athens Administrative Court of First Instance. The Group's legal department estimates that the settlement of the subject case will not have any material adverse effect on the Group's financial position and its operations.
On 27/11/2007 the subsidiary company of the Group SΟΝΑΚ S.A. filed an appeal for arbitration to the Court of Arbitration against the Greek State regarding a contract for the procurement of advanced technology systems. According to the signed contract dated 19/10/2001 between the contracting parties, i.e. the supplier company "SONAK S.A. " and the buyer namely the GREEK STATE, the contractual price for the procurement of these defense systems amounts to € 71.979 out of which, according to the payments stipulated in the contract, the supplier has received € 34.516 which represent the advance payment of
(Amounts are expressed in thousand Euros, unless otherwise stated)
50% of the total value after withholding the relevant legal deductions. According to article 12 of the Contract regarding the performance bond and guarantee granting, the supplier has deposited to the Greek State three letters of guarantee issued by ALPHA BANK for an amount of € 41.419. Furthermore, according to article 21 of the Contract, in case of failure of negotiations between the contracting parties, any dispute, doubt or disagreement regarding the application or interpretation of the terms and the extent of the rights and obligations arising from the contract in question, will be settled between the contracting parties and in case of failure it will be settled by arbitration according to the respective provisions of the Greek Legislation. The Company by relying on article 21 of the contract is seeking arbitration by the Court of Arbitration requesting that: 1) its appeal to arbitration is admitted; 2) the buyer pays the supplier an amount of € 39.281 including legal interest for the period starting 26/4/2003 or 1/9/2006 or after service of its appeal; 3) the buyer also pays an amount € 2.013 per annum from service of the appeal until its full settlement; 4) the buyer is awarded the entire court expenses (arbitrators' fees and expenses) and lawyers' fees; and 5) it is sentenced to a statement of intention to ALPHA BANΚ for its release from every obligation.
In frame of this pending arbitration, the Single-Member First Instance Court of Athens with the decision 7685/11.12.2008 accepted in its entirety the application dated 1/2/2008 by the subsidiary company for the exclusion of an arbitrator who was appointed by the opposing "GREEK STATE". Accordingly, the "GREEK STATE" had to appoint another arbitrator. Given the foregoing, the arbitration proceedings are currently in the process of composition of the arbitral tribunal, namely the selection of arbitrators or the court in the face of umpire.
The Group's management estimates that by the end of the current year the necessary documents and certificates are expected to be submitted.
On 30/9/2009 the Group had issued guarantees in order to secure liabilities from bank loans and finance lease contracts of subsidiaries and associate companies of a total amount € 69.991 (2008: € 62.591).
At 30/9/2009 the Group had concluded agreements for the operating lease of buildings and transportation means which are expected to end on various dates up to the year 2022.
The leases expenses arising from the operating lease of buildings and transportation means which were registered in the statement of comprehensive income of the closing period reached the amount of € 3.684 (2008: € 3.386).
The future minimum operating lease payments regarding buildings and transportation means on the basis of non-cancelable operating lease contracts are analyzed as follows:
| 30/9/2009 | 31/12/2008 | |
|---|---|---|
| Within 1 year | 4.946 | 4.139 |
| Between 2 and 5 years | 15.688 | 17.252 |
| Over 5 years | 14.009 | 9.142 |
| 34.644 | 30.533 |
The companies of the Group have not been audited by tax authorities for the following years:
| Companies | Tax unaudited fiscal years |
|---|---|
| ΑΧΟΝ HOLDINGS S.A. | 2008-2009 |
| Ι.Subsidiary companies | |
| EUROMEDICA S.A. | 2007-2009 |
| ORASIS HELLENIC OPTHALMOLOGICAL CENTER S.A | 2007-2009 |
| IPPOKRATIS CENTER OF NUCLEAR MEDICINE S.A. | 2007-2009 |
| MEDICAL DIAGNOSTIC LABORATORY YGEIA S.A. | 2007-2009 |
| MELAMBUS MEDICINE S.A. | 2007-2009 |
| THEOTOKOS MAIEYTIKI GYNEKOLOGIKI KLINIKI LARISAS S.A. | 2007-2009 |
| EUROMEDICA MULTIDIAGNOSTIC CENTER OF LARISA S.A | 2007-2009 |
| PYLI AXIOU PRIVATE DIAGNOSTIC CENTER S.A. | 2007-2009 |
| GENESIS MAIEYTIKI GYNECOLOGIKI KLINIKI THESSALONIKIS S.A | 2007-2009 |
| EUROMEDICA AROGI MEDICAL CENTER APOKATASTASI S.A. | 2003-2009 |
| GENERAL CLINIC OF DODEKANISA S.A. | 2007-2009 |
| EURO PROCUREMENT S.A. | 2008-2009 |
| SONAK S.A. | 2005-2009 |
| AXON SECURITIES S.A. | 2007-2009 |
| DATA DESIGN S.A. | 2007-2009 |
| MAGNETIC TOMOGRAPHY VOLOS S.A. | 2007-2009 |
| PRIVATE DIAGNOSTIC LABORATORY MEDICAL S.A. | 2007-2009 |
| EUROMEDICA PALAIOY FALIROY PRIVATE MULTIDIAGNOSTIC S.A. | 2006-2009 |
| YGEIA MAGNETIC DIAGNOSIS S.A. | 2007-2009 |
| EUROMEDICA FINANCE Νο 1 S.A. | 2007-2009 |
| TOURISTIC ENTERPRISES OF WEST MACEDONIA S.A. | 2004-2009 |
| EGEFALOS PELOPONISOU S.A. | 2007-2009 |
| ARISTOTELEIO IATRIKI S.A. | 2007-2009 |
| IONIA EUROMEDICA OF CORINTHOS S.A. | 2003-2009 |
| MEDIΝET ALEXANDROUPOLIS PRIVATE DIAGNOSTIC LABORATORY S.A. | 2003-2009 |
|---|---|
| AROGI S.A. | 2007-2009 |
| Companies | |
| APOKATASTASI S.A. | 2007-2009 |
| EUROMEDICA ANATOLIKI ATTIKI PRIVATE MULTI-MEDICAL FACILITYS S.A. | 2006-2009 |
| IONIOS GENERAL CLINIC S.A. | 2004-2009 |
| IATRIKI MEGARON PRIVATE DIAGNOSTIC LABORATORY S.A. | 2007-2009 |
| IONIA PRIVATE MULTI-MEDICAL FACILITY MEDICAL S.A | 2007-2009 |
| IONIA NEFROLOGIKI S.A. | 2007-2009 |
| GALINOS MEDICAL DIAGNOSTIC TRIKALON S.A. | 2007-2009 |
| MULTI-DIAGNOSTIC CENTER PIERIAS MEDICAL S.A. | 2007-2009 |
| PRIVATE NEUROPSYCHIATRIC CLINIC KASTALIA S.A. | 2007-2009 |
| IPPOKRATIS - MULTI-SPECIALTY DIAGNOSTIC CENTER SA | 2007-2009 |
| IPPOKRATIS MAGNETIC TOMOGRAPHY S.A | 2007-2009 |
| AXIAL TOMOGRAPHY N. IONIA S.A. | 2007-2009 |
| MEDICAL DIAGNOSIS OF LESVOS S.A. | 2008-2009 |
| MEDINET KAVALAS PRIVATE DIAGNOSTIC LABORATORY S.A. | 2008-2009 |
| EUROMEDICA AROGI ACHAIAS S.A. | 2008-2009 |
| ΕUROMEDICA LYDIA KAVALAS S.A. | 2008-2009 |
| ZOE GENIKI THERAPEFTIKI PRIVATE CLINIC S.A. | 2008-2009 |
| EUROMEDICA ALBANIA HOLDING S.A. | 2008-2009 |
| IONIA-EUROMEDICA PRIVATE MULTI-MEDICAL FACILITY S.A. | 2008-2009 |
| DIAGNOSTIC CENTER IKEDA LTD | 2005-2009 |
| ΑΧΟΝ MANAGEMENT S.A. | 2008-2009 |
| ΑΧΟΝ FINANCE S.A. | 2007-2009 |
| PRIVATE DIAGNOSTIC LABORATORY EURODIAGNOSI CORFU S.A. | 2008-2009 |
| EUROMEDICA SERRES S.A. | 2006-2009 |
| DIAGNOSTIC CENTER LARISA S.A. | 2007-2009 |
| NEUROLOGIC PSYCHIATRIC CLINIC A. PISSALIDIS – A. KARIPIS S.A. | 2007-2009 |
| PRIVATE DIAGNOSTIC LABORATORY ALEXANDRIO S.A. | 2007-2009 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| PRIVATE DIAGNOSTIC LABORATORY OF W. THESSALONIKI S.A. | 2007-2009 |
|---|---|
| AXIAL DIAGNOSIS S.A. | 2008-2009 |
| EUROMEDICA THERAPY AND RESTITUTION CENTER S.A. | 2007-2009 |
| Companies | |
| VOGIATZIS PRIVATE DIAGNOSTIC LABORATORY S.A. | 2008-2009 |
| EUROMEDICA TRIKALA S.A. | 2008-2009 |
| KASTALIA ACHAIA S.A. | 2008-2009 |
| D.S. SIOVAS – RADIODIAGNOSTIC CENTER GREVENA S.A. | 2008-2009 |
| ASKLEPIEIO INFIRMARY LARISA S.A. | 2008-2009 |
| S.K.D.S. MANAGEMENT ADVISORS S.A. | 2007-2009 |
| EUROMEDICA REAL ESTATE | 2009 |
| EUROMEDICA GALATSIO S.A. | 2009 |
| ALPHA NEFRODINAMIKH | 2008-2009 |
| EUROMEDICA KRETE | 2009 |
| ΙΙ. Associates | |
| EUROGENETIKI S.A. | 2006-2009 |
| MEDITRON S.A. | 2003-2009 |
| DORMED HELLAS S.A. | 2003-2009 |
| MEDICAL DIAGNOSTIC LABORATORY KOZANI S.A. | 2007-2009 |
| MEDITREND S.A. | 2008-2009 |
| MEDICAL MULTIDIAGNOSTIC LABORATORY OF KARDITSA S.A. | 2006-2009 |
| EUROMEDICA WESTERN MACEDONIA THERAPY AND RESTITUTION CENTER | 2008-2009 |
| EUROMEDICA-COSMETIC PRIVATE POLYIATREIO S.A. | 2009 |
In the closing period, the tax obligations of the followings companies of the Group were finalized:
| n/n | Company | Tax audited fiscal years |
Additional taxes and surcharges emerged |
|---|---|---|---|
| 1 | ΑΧΟΝ HOLDINGS S.A. | 2005-2007 | 557 |
| 2 | EUROMEDICA S.A. | 2006-2008 | 603 |
| 3 | GENERAL CLINIC OF DODEKANISA S.A. | 2000-2006 | 62 |
| 4 | TOURISTIC ENTERPRISES OF WEST MACEDONIA S.A. | 2000-2006 | 3 |
| 5 | ΑΧΟΝ SECURITIES S.A. | 2005-2006 | 31 |
(Amounts are expressed in thousand Euros, unless otherwise stated)
| Total taxes from previous years disclosed in the statement of comprehensive income | ||||||
|---|---|---|---|---|---|---|
| 11 | AXIAL DIAGNOSIS S.A. | 2007-2008 | 12 | |||
| 10 | PRIVATE DIAGNOSTIC LABORATORY EURODIAGNOSI CORFU S.A. | 2003-2006 | 5 | |||
| 9 | IPPOKRATIS MAGNETIC TOMOGRAPHY S.A. | 2005-2006 | 3 | |||
| 8 | MULTI-DIAGNOSTIC CENTER PIERIAS MEDICAL S.A. | 2002-2006 | 2 | |||
| 7 | IONIA EUROMEDICA OF CORINTHOS S.A. | 2004-2006 | 1 | |||
| 6 | ARISTOTELEIO IATRIKI S.A. | 2003-2006 | 2 | |||
At the end of the year 2008, The Management of the Group as indicated in detail in Note 5, changed the accounting policy regarding the formulation of provisions for additional taxes for tax unaudited fiscal years, forming the necessary provisions for additional taxes that may arise in future tax audit of unaudited fiscal years, according to the findings of previous years' tax audits and previous interpretations of tax laws. From the finalization of the tax liabilities of the above subsidiaries, there was no further charge for the Group because the provisions that were made covered the amounts of taxes that were provoked. On 30/9/2009 the cumulative provision amounts to € 3.139 (2008: € 4.113) for the Group and € 393 (2008: € 860) for the Company.
Apart from the aforementioned facts, there are no further events after the Financial Statement Position date i.e. the 30th September 2009, regarding the Group, worth to be noted based on the obligations and rules dictated by the IFRS.
Athens, 23 November 2009
The President of the Board The Chief Executive Officer Head of the Accounting Department
Apostolos D. Terzopoulos Panagiotis N. Doumanoglou Loukas S. Liakos I.C. No Σ 636315/98 I.C. No Σ 232215/00 I.C. No Τ 017003
License Number Economic Chamber of Greece 38962 Α´ DEGREE
| Company's website address: |
|---|
| Date of approval of the financial statements |
| by the Board of Directors. |
| Certified Auditor: |
| Audit Company: |
| the project of the control of the control of |
| STATEMENT OF FINANCIAL POSITION (consolidated and non consolidated) Amounts in thousands of Euro |
(consolidated and non consolidated) Amounts in thousands of Euro | STATEMENT OF COMPREHENSIVE INCOME | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GROUP | COMPANY | GROUP | COMPANY | ||||||||||
| ASSETS | 30/09/2009 | 31/12/2008 | 30/09/2009 | 31/12/2008 | 1/1-30/9/09 | 1/1-30/9/08 | 1/7-30/9/09 | 1/7-30/9/08 | 1/1-30/9/09 | 1/1-30/9/08 | 1/7-30/9/09 | 1/7-30/9/08 | |
| Property, plant and equipment | 397,270 | 370.186 | 4,267 | 4.588 | Turnover | 195.404 | 187.000 | 60.634 | 57.620 | 2.561 | 5.417 | 641 | 2.432 |
| Investment property | 30.638 | 30.628 | 34.881 | 34.871 | Gross profit (loss) | 42.261 | 36.526 | 12.584 | 11,212 | 246 | 872 | [15] | 921 |
| Intangible assets | 137.578 | 136.040 | 774 | 1.421 | Earnings before | ||||||||
| Other non-current assets | 64.683 | 72.709 | 113.327 | 114.927 | interest and Tax | 22.229 | 16.749 | 5.275 | 5.771 | 36 | 470 | [41] | 684 |
| Inventories | 26.074 | 27.064 | 62 | 1.162 | E.B.I.T.D.A. | 34.832 | 29.479 | 9.614 | 10.638 | 1.023 | 2.254 | 306 | 1.027 |
| Trade receivables | 125.487 | 109.825 | 1.274 | 1,789 | Profit / (loss) before tax | 6.344 | [13.665] | (1.619) | 1.348 | (1.410) | 187 | (466) | 456 |
| Other current assets | 132.695 | 122.738 | 351 | 248 | Profit / (loss) after tax (A) | 3.877 | [11.801] | (1.952) | 3.641 | (1.315) | 951 | (410) | 949 |
| Non current assets available for sale | - Parent Shareholders | 412 | (8.188) | (1.920) | 1,846 | (1.315) | 951 | (410) | 949 | ||||
| TOTAL ASSETS | 914.424 | 869.189 | 154.936 | Minority interests | 3.465 | (3.613) | (31) | 1.795 | $\Omega$ | ||||
| 159.005 | Other comprehensive income after tax (B) | 622 | (1.012) | (1.013) | (1.012) | 44 | $\theta$ | ||||||
| EQUITY AND LIABILITIES | Total comprehensive income | ||||||||||||
| Share capital | 24.712 | 24.712 | 24.712 | 24.712 | $after tax(A) + (B)$ | 4.499 | (12.813) | (2.965) | 2.629 | (1.271) | 951 | [410] | 949 |
| Other Shareholders' Equity items | 84.139 | 83.910 | 73.201 | 74.472 | - Parent Shareholders | 799 | (9.026) | [2.573] | 1,009 | (1.271) | 951 | (410) | 949 |
| Parent company shareholders' equity (a) | 108.851 | 108.622 | 97.913 | 99.184 | - Minority interests | 3,700 | (3.788) | [392] | 1.620 | $^{\circ}$ | $\theta$ | ||
| Minority Interests [b] | 116.389 | 116,714 | Earnings / (loss) per share after | ||||||||||
| Total Equity $[c] = [a] + [b]$ | 225.240 | 225.336 | 97.913 | 99.184 | tax - basic (in €) | 0,0106 | (0.2140) | (0,0505) | 0.0481 | (0,0326) | 0.0236 | (0.0101) | 0.0235 |
| Long term bank borrowings | 313.761 | 301.497 | 35.489 | 35.969 | Earnings / (loss) before tax, financial | ||||||||
| Provisions and other long term liabilities | 40.237 | 42.511 | 7,360 | 7.956 | and investing results and | ||||||||
| Short term bank borrowings | 118.725 | 108.700 | 10.777 | 10.595 | total depreciation | 34.912 | 29.471 | 9.715 | 10.568 | 1.023 | 2.016 | 306 | 1.056 |
| Other short term liabilities | 216.461 | 191.145 | 3.395 | 5.299 | |||||||||
| Liabilities associated with non-current assets | CASH FLOW STATEMENT | ||||||||||||
| available for sale | O | (consolidated and non consolidated) Amounts in thousands of Euro | |||||||||||
| Total liabilities (d) | 689.184 | 643.853 | 57.022 | 59.821 | GROUP | COMPANY | |||||||
| TOTAL EQUITY AND LIABILITIES (c) +(d) | 914.424 | 869.189 | 154.936 | 159.005 | Cash flows from operating activities. | 1/1-30/09/2009 1/1-30/09/2008 | 1/1-30/09/2009 | 1/1-30/09/2008 | |||||
| STATEMENT OF CHANGES IN EQUITY | Earnings / (losses) before tax | 6.344 | (13.665) | (1.410) | 187 | ||||||||
| fconsolidated and non consolidated] Amounts in thousands of Euro | Plus (less) adjustments for: Depreciation and amortisation expenses |
12.783 | 12.832 | 987 | 1.546 | ||||||||
| GROUP | COMPANY | Provisions | 634 | 2.362 | (523) | ||||||||
| 30/09/2009 | 30/09/2008 | 30/09/2009 | 30/09/2008 | Loss / [gain] from disposal of fixed assets | 180 | 102 | [237] | ||||||
| Total equity at the beginning of the period | Loss / (gain) from participations in associates | 2.859 | 16,805 | (552) | |||||||||
| $m_1$ instruction and superinted accompatible in | one one | SEO EOO | 0.015 | 503,602 | Americalism of excessions at ansatz | 11003 | 11101 |
| ,,,,,,,,,,,, | JUI UJI EUUU | JW JJrsuuJ | ---- | |
|---|---|---|---|---|
| Total equity at the beginning of the period | ||||
| (01/01/2009 and 1/01/2008 respectively) | 225.337 | 258,588 | 99.184 | 10 |
| Total comprehensive income after tax | 4.499 | [12.813] | (1.271) | |
| Changes in share capital | (4.051) | $\overline{a}$ | ||
| Share capital increase expenses | (586) | |||
| Dividends paid | (3.082) | (1.402) | ||
| Change in existing subsidiaries' participating interests | ||||
| and consolidation of new subsidiaries | [1.514] | (5.534) | ||
| Movement in treasury shares | (143) | |||
| Total equity at the end of the period | ||||
| (30/09/2009 and 30/09/2008 respectively) | 225.240 | 234.058 | 97.913 | 9 |
| GROUP | COMPANY | |||
|---|---|---|---|---|
| 1/1-30/9/2009 | 1/1-30/9/2008 | 1/1-30/9/2009 | $1/1 - 30/9/2$ | |
| Revaluation of assets at fair value | 778 | 4.2321 | ||
| Income tax over the other comprehensive income | (156) | 3.220 | (15) | |
| Other comprehensive income after tax | 622 | (1.012) |
| . | 11131704361 GROUP |
COMPANY | |||
|---|---|---|---|---|---|
| 1/1-30/09/2009 1/1-30/09/2008 | 1/1-30/09/2009 1/1-30/09/2008 | ||||
| Cash flows from operating activities. | |||||
| Earnings / (losses) before tax | 6.344 | (13.665) | (1.410) | 187 | |
| Plus (less) adjustments for: | |||||
| Depreciation and amortisation expenses | 12.783 | 12832 | 987 | 1.546 | |
| Provisions | 634 | 2.362 | 41 | (523) | |
| Loss / [gain] from disposal of fixed assets | 180 | 102 | ٥ | [237] | |
| Loss / (gain) from participations in associates | 2.859 | 16,805 | Ō | (552) | |
| Amortisation of government grants | (100) | (110) | ٥ | o | |
| Income from participations | (1.269) | [1.775] | Ũ | (1.008) | |
| Loss / [gain] from investments | (20) | (535) | ũ | o | |
| Debit interest and other related expenses | 12.660 | 15.949 | 1,446 | 2.080 | |
| 34.071 | 31.964 | 1.064 | 1.494 | ||
| Plus / (less) adjustments for changes in working | |||||
| capital or operating activities accounts: | |||||
| fincrease) / decrease in inventories | 1.011 | 3.228 | 1,100 | 187 | |
| (increase) / decrease in trade and other receivables | (29.083) | (13.630) | 482 | 781 | |
| Increase / (decrease) in payables (less loans) | 34.954 | (31.579) | 1.106 | (14.860) | |
| (Less). | |||||
| Debit interest and other related expenses paid | (13.284) | (15.625) | (1.446) | (2.109) | |
| Income taxes paid | (8.112) | [12.957] | [415] | (2.012) | |
| Net cash (used in) / generated from operating activities (a) | 19.557 | (38.599) | 1.891 | (16.519) | |
| Cash flows investing activities: | |||||
| Acquisitions of subsidiaries, affiliates, joint ventures and other investments (19.331) | [56.035] | (100) | (11.225) | ||
| Purchase of treasury shares | ō | (143) | õ | (54) | |
| Purchase of tangible & intangible assets | (39.208) | [35.254] | o | (339) | |
| Proceeds from tangible and intangible assets sales | 78 | 698 | Ũ | 14.374 | |
| Proceeds from financial assets and investment sales | 14.272 | 25.159 | 1.720 | 3.476 | |
| Proceeds from financial assets | |||||
| г | ũ | ٥ | ٥ | ||
| Interest received | 622 | 854 | ٥ | 29 | |
| Proceeds from government grants | ٥ | 4 | ٥ | $\theta$ | |
| Dividends received | 1.269 | 1.803 | o | 1.008 | |
| Net cash used in investing actibities (b) | (42.297) | (62.914) | 1.621 | 7.267 | |
| Cash flows from financing activities. | |||||
| Proceeds from / Repayment of loans | 22.302 | 108,090 | (3.402) | 9.526 | |
| Repayment of finance lease liabilities | 766 | (2.180) | ٥ | 0 | |
| Dividends paid | (3.793) | (3.503) | [29] | [273] | |
| Board of Directors' fees | (1.383) | [611] | ٥ | ٥ | |
| Net cash generated from / (used in) financing activities (c) | 17.893 | 101.795 | (3.432) | 9.252 | |
| Net increase (decrease) in cash 22 | |||||
| cash equivalents $(a) + (b) + (c)$ | (4.848) | 281 | (80) | 1 | |
| 38.386 | 30.842 | 152 | 363 | ||
| Cash & cash equivalents at the beginning of the period | |||||
| Cash & cash equivalents at the end of the period | 33.538 | 31.123 | 232 | 364 | |
| Total comprehensive income after tax | |||||
| PERIOD | Balance brought forward | Adjusted Balance (see notes 5 20 13) | |||
| GROUP | COMPANY | GROUP | COMPANY | ||
| 1/1-31/12/2008 | (20.375) | 457 | (20.724) | 457 |
| those of the respective period of the previous year, are the following. EUROMEDICA COSMETIC PRIVATE POLYIATRIO S.A. on | Total equity attributed to parent company shareholders. | ||||
|---|---|---|---|---|---|
| 31/3/2009 (participating interest 22,71%), EUROMEDICA WESTERN MACEDONIA RECOVERY AND REHABILITATION CENTER KOZANIS S.A. on 24/11/2008 (participating interest 15.53%). |
PERIOD | Balance brought forward | Adjusted Balance (see notes 5 20 13) | ||
| 8. The Subsidiary companies acquired (see note 3 to the financial statements) and included in the consolidated financial statements | GROUP | COMPANY | GROUP | COMPANY | |
| of the closing period, which had not been included in the financial statements of the previous period or in those of the respective | 1/1-31/12/2008 | 108,701 | 99.184 | 108.622 | 99.184 |
| period of the previous year, are the following: VOGIATZIS PRIVATE DIAGNOSTIC LABORATORY S.A. on 3/9/2008 (participating | 1/1-30/9/2008 | 115,607 | 106 446 | 114,411 | 99.662 |
| interest 29.86%), AXONIKI DIAGNOSIS S.A. on 13/11/2008 (participation rate 62.22%), SIOVAS - X-RAY CENTER S.A. on 1/2/2009 | |||||
| (participating interest 30.49%), MEDICAL SERVICES RECOVERY AND RECOVERY S.A. on 1/3/2009 (participating interest 37.33%) | Profit after tax and minority interests | ||||
| and ALPHA NEFRODYNAMIKI S.A. on 28/8/2009 [participating interest 29.24%]. | PERIOD | Balance brought forward | Adjusted Balance (see notes 5 2 13) | ||
| The associate company of the Group (see note 3 to the financial statements) which was acquired on 30/6/2009 and was | GROUP | COMPANY | GROUP | COMPANY | |
| consolidated in financial statements of the closing period, by the equity method and which had not been included in the financial | 1/1-31/12/2008 | 27.875 | 99.184 | 27.839 | 159,005 |
| statements of the respective period of the previous year, is the company CENTRAL MEDICAL SERVICES S.A. [participating interest | 1/1-30/9/2008 | 27,885 | 8.393 | 29.419 | 7.625 |
| 17.73%). | |||||
| 9. The subsidiary company S.K.D.S. MANAGEMENT ADVISORS S.A. (ex EUROHOSPITAL S.A.) was consolidated by the Equity method, in the consolidated financial statements on 30/9/2008 and 31/12/2008, whereas on 30/9/2009 by the total consolidation method, due to the undertaking of its business activities management. 10. There are mortgage prenotations on the real estate property of the Group and the Company, amounting to € 93.534 k. and € 24.800 k, respectively, for granted loans, letters of guarantee and guarantees concerning debt to the Greek state with an |
13. Investments in fixed assets for the closing period amounted to € 39.208 k, for the Group and € 0 k, for the Company. 14. The cumulative amounts of income and expenses from the beginning of the fiscal year and the balances of receivables and payables of the Group and the Company at the end of the closing period, that have emerged from transactions with related parties as are they defined by IAS 24, are analyzed as follows: (Amounts in thousands of euro) |
||||
| outstanding balance as at 30/9/2009 of € 163.489 k, and € 75.569 k, respectively. | GROUP | COMPANY | |||
| 11. The number of employees of the Group and the Company at the end of the closing period was 2.702 and 8 respectively. | al Income | 365 | 291 | ||
| The number of the employees of the Group and the Company at the end of the respective last year closing period was 2.503 and 15 | b) Expenses | 2.441 | 13 | ||
| respectively. | c) Receivables | 27.344 | 39 | ||
| 12. The equity and results of the comparative financial statements were revised due to accounting for the provision of the unaudited tax years and the finalization of temporary goodwill. |
d) Payables | 10.096 | 607 | ||
| This resulted in the following (Amounts in thousands of Euro) | e) Transactions and remuneration of management executives and board members | 333 | 111 | ||
| f) Receivables from management executives and board members | |||||
| g) Payables to management executives and board members | |||||
| 15. E.B.I.T.D.A. is defined as Earnings before interest, income taxes, depreciation and amortization (amortisation of government grants and loss/gain from disposal of fixed assets are not included). 16. Any small differenses are due to figure rounding |
|||||
| Athens, November 23 2009 | |||||
| Chairman of the Board of Directors | The Managing Director | The Head of the Accounting Department | |||
| TERZOPOULOS APOSTOLOS ID. No. Σ 636315/98 |
PANAGIOTIS DOUMANOGLOU ID.No. Σ 232215/00 |
LOUKAS LIAKOS ID. No. T 017003 ECONOMIC CHAMBER OF GREECE LICENCE No 38962 A' CLASS |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.